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Summary 
Patients with peripheral arterial disease (PAD) can only walk so far before they get leg 
pain (intermittent claudication) and have to stop.  They are also at risk in the future of 
needing amputation of one of their limbs.  Allopurinol is a new possible treatment for 
this condition as it has been shown in coronary arterial disease to prolong exercise 
before angina pain occurs. 
 
This is thought to be because allopurinol can both prevent oxygen wastage in tissues 
and prevent the formation of harmful oxidative stress.  We hypothesised that 
allopurinol could prolong the time to leg pain in participants with PAD. 
 
In a double-blind, randomised controlled clinical trial 50 participants with PAD were 
randomised to receive either allopurinol 300mg twice daily or placebo for six months.  
The primary outcome was change in exercise capacity on treadmill testing at six 
months.  Secondary outcomes were six-minute walking distance, Walking Impairment 
Questionnaire, SF-36 QoL questionnaire, flow-mediated dilatation and oxidised LDL.  
Outcome measures were repeated mid-study and at end of study. 
 
The mean age of participants was 68.4 years (SD 1.2) with 39/50 (78%) male.  Only five 
participants withdrew in the course of the study, two in the active group and three in 
the placebo group.  There was a significant reduction in uric acid levels in those on 
active treatment of 52.1% (p<0.001), but no significant change in either the pain-free 
or the maximum distance they were able to walk.  Other measures of exercise 
20 
 
capacity, blood vessel function and the participants’ own assessment of their health 
and walking ability also did not change during the course of the study. 
 
In summary, although allopurinol has been shown to be of benefit in a number of 
other diseases, in this study there was no evidence of any improvement following 
treatment in patients with peripheral arterial disease. 
  
21 
 
1 Introduction 
1.1 Peripheral Arterial Disease 
1.1.1 Epidemiology 
Peripheral arterial disease (PAD) is a disease that carries with it significant morbidity 
and through links with cardiovascular disease, mortality.  The total disease prevalence 
has been estimated at 3-10%, rising with age to 15-20% in those over 70 years of age.1-
3  In Europe and North America alone over 27 million people are thought to be affected 
by it.4  However much of this disease is asymptomatic, as demonstrated by the 
Edinburgh Artery Study.5  In their study population (an age-stratified sample of men 
and women aged 55-74 years across ten general practices in the city) the researchers 
found major asymptomatic disease leading to a significant impairment in blood flow in 
8% of participants, despite a prevalence of symptoms of intermittent claudication of 
only 4.5%.  These figures for prevalence of symptomatic disease are certainly in-
keeping with the 3-7% figures quoted elsewhere in the literature.6, 7  There is an 
approximately two-fold increase for males compared to females, although an element 
of this may be due to historically higher smoking rates in men and may change slightly 
in the future given the relative shift in smoking habits from men to women in recent 
years.7, 8 
 
Patients with major asymptomatic disease had a 60% increase in relative risk of 
cardiovascular disease.5  The concept that asymptomatic patients with PAD were at 
significant mortality risk was confirmed by Criqui and colleagues when they looked at 
22 
 
mortality over a 10 year period in patients with PAD (the San Diego Artery Study), as 
illustrated by the Kaplan-Meier survival plot in Figure 1.9 
 
Figure 1 – Survival rate of patients with PAD by symptom, compared to non-PAD patients 
 
The cornerstone of treatment of PAD therefore remains identification and treatment 
of cardiovascular risk factors, however from a patient perspective the most troubling 
problem remains that of intermittent claudication.10 
 
1.1.2 Pathophysiology 
PAD refers to the obstruction of the large arteries outwith the coronary and cerebral 
circulation, mainly in the lower extremities.  These narrowings develop and progress 
through the process of atherosclerosis.11  The clinical events resulting from 
atherosclerosis are directly related to the oxidation of lipids in LDLs that become 
trapped in the extracellular matrix of the subendothelial space.  The eventual 
progression of the lesion is associated with the activation of genes that induce arterial 
23 
 
calcification, which changes the mechanical characteristics of the artery wall.  These 
changes in the vessel wall (in particular the oxidation of lipids) predisposes to plaque 
rupture at sites of monocytic infiltration.  Plaque rupture exposes the flowing blood to 
tissue factor in the lesion, and this induces thrombosis, which is the proximate cause of 
the clinical event.12 
 
There are a number of key risk factors involved in this process of lipid infiltration, 
changed mechanical characteristics of the artery wall and cell damage.  These include 
hypertension, hypercholesterolaemia, and diabetes mellitus.  Analysis of data from the 
Framingham study provided useful information regarding the first two of these, 
showing that a BP of >160/95 led to a 2.5x relative increase in risk for men and 4x 
relative increase for women.  A fasting cholesterol concentration of >7mmol/L was 
associated with a two-fold increase in risk of claudication.13  It has also been shown 
that in patients with metabolic syndrome that the more components of the syndrome 
they exhibited* the worse their intermittent claudication, physical function, health-
related quality of life, and peripheral circulation.14 
 
With regards diabetes mellitus, the UK Prospective Diabetes Survey showed that 
hyperglycemia (assessed as HbA1c) was associated with an increased risk for incident 
PVD, independent of other risk factors including age, increased systolic blood pressure, 
reduced HDL cholesterol, smoking, prior cardiovascular disease, peripheral sensory 
                                                       
* The five key components of metabolic syndrome as defined by the National Cholesterol Education 
Programme Adult Treatment Panel (NCEP ATP III) consist of: (1) abdominal obesity (waist circumference 
>102 cm in men and >88 cm in women); (2) elevated triglycerides (≥150 mg/dL); (3) reduced high-
density lipoprotein cholesterol (<40 mg/dL in men and <50 mg/dL in women); (4) elevated blood 
pressure (≥130/85 mm Hg); (5) elevated fasting glucose (≥110 mg/dL) as well as those with diabetes. 
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neuropathy, and retinopathy. Each 1% increase in HbA1c was associated with a 28% 
increased risk of PVD (95% CI 12–46), and each 10-mmHg increase in systolic blood 
pressure with a 25% increase in risk (95% CI 10–43).15 
 
The relative risk of these different factors is shown in Figure 2.1  Although careful blood 
glucose control for patients with diabetes and control of both hypertension and 
hypercholesterolaemia is certainly beneficial, the major modifiable risk factor for the 
development of PAD is smoking.  This relationship has been known about for over a 
century now, following the observation by Erb in 1911 that intermittent claudication 
was three times more common amongst smokers compared to non-smokers.1  There is 
a dose-response relationship with a relative risk of 3.7 in current smokers compared to 
3.0 in those who had given up smoking within the past five years.5  The link between 
smoking and PAD appears to be even stronger than the one between smoking and 
CHD.1  Passive smokers can be adversely affected too, with repeated exposure to 
second-hand smoke nearly doubling the risk of development of PAD in non-smokers.16  
The failure rate for those with surgical bypass grafts is also three times higher in 
patients who continue to smoke, something that may be partially reversed by smoking 
cessation.17 
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Figure 2 – Approx. range of odds ratios for risk factors for symptomatic PAD 
 
Following a clinical suspicion of PAD, the simplest way to confirm the diagnosis is 
through measurement of the ankle-brachial index (ABI – also sometimes referred to as 
the ankle-brachial pressure index, ABPI).  This involves measuring the systolic blood 
pressure in the brachial, posterior tibial and dorsalis pedis arteries.  The highest of the 
leg measurements on each side is divided by the higher of the two brachial 
measurements, with a normal value being 1.0-1.3.18  An ABI below 0.9 has 95% 
sensitivity and 100% specificity for detecting angiogram-positive PAD and is associated 
with a greater than 50% stenosis in at least one major blood vessel.4  A relatively high 
ABI (>1.4) normally signifies calcification of the arteries and increased levels of 
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cardiovascular risk.  Some alternate measures, such as ankle-arm index, have also been 
tested but none have gained the same widespread acceptance as ABI.19 
 
1.1.3 Claudication pain in PAD patients 
In symptomatic patients with PAD, the limited arterial supply to the lower extremities 
cannot meet the dynamic metabolic demand of the muscles during ambulatory 
activities, leading to the development of pain.20, 21  The classical description of this in a 
patient with PAD is an aching muscular leg pain brought on by exertion that is rapidly 
relieved by rest (normally within ten minutes) – this is known as intermittent 
claudication.  Unlike other disease processes such as osteoarthritis, there is an initial 
pain-free walking distance before the onset of pain.22  Walking faster or up a steeper 
gradient (i.e., increasing the metabolic demand on the muscles) brings the pain on 
more quickly.  However there is an inevitable heterogeneity between patients as to 
the level of exertion required to bring on pain.  Interestingly the rate of symptomatic 
progression in PAD appears to be reasonably steady, at around 25% of patients with IC; 
this is most frequent during the first year after diagnosis (7%–9%) compared with 2% 
to 3% per year thereafter.1  This relative stability of symptoms may be due to the 
development of collaterals, metabolic adaptation of ischaemic muscle, or the patient 
altering their gait to favour non-ischaemic muscle groups.1  It may also be due to 
patients altering their physical activity levels to compensate – for example by walking 
more slowly.23, 24 
 
The Fontaine scheme classifies four stages of peripheral arterial disease.  Peripheral 
arterial disease can be asymptomatic (Fontaine stage I) or symptomatic (Fontaine 
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stages II–IV).  The most common symptom of peripheral arterial disease is intermittent 
claudication (Fontaine stage II), which is characterised by pain in the legs or buttocks 
that occurs with exercise and is relieved with rest.  Two further stages exist: pain in the 
extremities at rest (ischaemic rest pain, Fontaine stage III) and necrosis and gangrene 
(Fontaine stage IV).25 
 
Patients with IC often experience a diminishing quality of life as their walking speed 
and range worsen, leading to progressively limited mobility and independence and the 
consequent detrimental effect on their mental health and well-being.4, 26, 27  However 
the claudication symptoms of PAD are not as well-recognised by the general public (or 
indeed at times the medical profession) compared to angina, the analogous symptom 
for CHD.28  This tends to lead to a delay in seeking medical help (population screening 
studies have suggested between 10-50% of patients with symptoms of IC have not 
sought medical help regarding their symptoms1) with the consequent progression of 
disease (and risk of other cardiovascular events) in the meantime. 
 
The location of the claudication symptoms tends to correspond with the source of the 
arterial lesion, as outlined in Table 118 and Figure 322. 
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Artery Symptoms 
Aortoiliac 
(Leriche syndrome) 
Buttock, hip and in some cases thigh claudication; bilateral 
severe aortoiliac disease can cause impotence in men 
Common femoral 
Thigh, calf claudication or both; patients have normal groin 
pulses but diminished pulses distally 
Superficial femoral Upper two-third of calf claudication 
Popliteal Lower third of calf claudication 
Tibial or peroneal 
Isolated foot claudication is rarely seen with atherosclerotic 
occlusive disease but is commonly seen with 
thromboangiitis obliterans (Buerger’s disease) 
Table 1 – Correlation between claudication symptoms and lesion location 
 
 
Figure 3 – Arteries of the lower limb 
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This pain is due to build-up of anaerobic metabolites, mainly lactic acid.29  This is 
formed through the ischaemic cascade.30  The lack of oxygen delivery to the myocytes 
leads to failure of the normal processes for ATP formation and for cells to switch to 
anaerobic metabolism, producing lactic acid.  The ATP-reliant cell membrane transport 
pumps also fail, leading to rising intracellular Ca2+ levels.  This excess calcium leads to 
the generation of free radicals, reactive oxygen species and calcium-dependent 
enzymes such as calpain, endonucleases, ATPases, and phospholipases in a process 
called excitotoxicity.31-33  The reduction in ATP production also leads to inefficient use 
of the electron transport chain in the mitochondria, with a consequent reduction in 
superoxide dismutase and increase in reactive oxygen species.34 
 
1.1.4 Disease progression 
The most worrying complication of PAD is critical limb ischaemia (CLI).  This is 
characterised by ulceration, gangrene, or rest pain consistently for more than two 
weeks.  This should be differentiated from benign night-time calf cramps – true rest 
pain usually affects the toes or foot of the affected limb and patients often describe 
hanging the affected limb out of bed to ease symptoms.22  Thankfully this is a relatively 
rare outcome of claudication, with only 1% to 3.3% of patients with IC needing major 
amputation over a five-year period.1  Those with diabetes and those who continue to 
smoke are however at significantly increased risk.  Figure 4 shows the approximate 
magnitude of the effect of different risk factors on the development of CLI.1 
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Figure 4 – Approx. magnitude of the effect of risk factors on development of CLI 
 
Interestingly, although some patients will experience a gradual progression of 
symptoms (from asymptomatic PAD through to CLI), more than half of patients 
undergoing amputation for CLI were not troubled by ischaemia in the six months prior 
to surgery.35  However patients with PAD often have significant comorbidities, 
therefore the lack of ischaemic symptoms in these patients may also be a reflection of 
their limited physical mobility.22 
 
Unsurprisingly there is also a great overlap between PAD and atherosclerosis of other 
parts of the circulatory system, particularly the coronary and cerebrovascular 
circulation.  The REACH Registry (67,888 patients) provides some excellent information 
regarding this overlap between circulatory system disease, as illustrated in Figure 5.36, 
37 
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Figure 5 – Overlap of vascular disease in different arterial systems (created from REACH study data) 
 
As a result of this overlap it is estimated that 2-4% of PAD patients have a non-fatal 
cardiovascular event every year.  The risk is higher in the first year after developing IC, 
but remains higher at all times than the risk of ever requiring amputation for leg 
ischaemia.38 
 
The mortality of patients with known PAD (mainly those with IC) is quoted at 30% at 
five years, 50% at ten years, and 70% at 15 years, without any clear improvement in 
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these figures in the past few decades.  The overall mortality is approximately two-and-
a-half times that of an age-matched general population.38 
 
1.1.5 Therapeutic options 
As highlighted above, the elevated mortality risk in patients with PAD is mainly due to 
increased deaths from cerebrovascular disease (CVD) and coronary heart disease 
(CHD).  Criqui et al demonstrated a RR of 3.1 of all-cause mortality in PAD patients, 
rising to 5.9 when looking at death due to CVD and 6.6 for death due to CHD.9  This 
increase in risk persisted even in patients without known pre-existing CHD, albeit 
falling slightly to 4.3. 
 
Cardiovascular risk factor modification therefore remains a mainstay of treatment, 
with an antiplatelet agent such as aspirin or clopidogrel being recommended.1, 10, 39  
Although the benefits of anti-platelet therapy may not be as marked for patients 
without co-existing CVD, an overall odds reduction of around one-fifth has been shown 
across all subgroups of patients with PAD40, making it a good baseline treatment.  The 
CAPRIE study (an RCT of 19,185 patients with all forms of cardiovascular disease) found 
clopidogrel to be more effective than aspirin, with a relative risk reduction of 8.7% for 
MI, stroke and vascular death.22, 41  A subgroup analysis of patients with PAD indicated 
a 23.8% relative risk reduction in favour of clopidogrel.  There had previously been cost 
concerns regarding prescription of clopidogrel relative to aspirin, however in June 
2009 it came off-patent in the EU and equally efficacious generic forms were 
licensed.42, 43 
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Other risk factors such as hypertension, hypercholesterolaemia and 
screening/treatment for diabetes all also need addressed.44  As well as reducing 
cardiovascular risk these treatments can sometimes have a positive effect on 
claudication symptoms.  In particular for statin therapy there is evidence that high 
dose simvastatin and atorvastatin can lead to improved 6-minute walking distance and 
walking velocity.45-47  The risk factor modification that can bring the greatest benefit to 
patients though is smoking cessation – it is critical that this is clearly explained to any 
patient diagnosed with PAD. 
 
However in symptomatic patients, once risk factor modification has taken place there 
remains the problem of the claudication pain.  To address this there are three main 
therapeutic options – exercise programmes, pharmacological therapy and intervention 
(through either the endovascular or surgical approach). 
 
Hiatt et al produced a flowchart for therapies in PAD that has also received the backing 
of the Trans-Atlantic Inter-Society Consensus document taskforce (TASC II) and is 
shown in Figure 6.1, 48 
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Figure 6 – Flowchart of therapy selection in PAD 
 
Exercise 
This treatment category has historically been quite heterogeneous, ranging from 
providing standardised advice to patients to “take more exercise”, to one-on-one 
counselling sessions, to regular supervised exercise classes using treadmills.49  There is 
evidence that supervision helps in the achievement of optimal results and this can be 
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to quite reasonable clinical benefit.50  One large trial showed an approximately 150m 
increase in walking distance (from a baseline of 300m), with an effect size of 0.58 at 
three months, maintained to 0.89 at six months.1, 51  There is inadequate evidence at 
present to attribute the functional benefit from exercise to the growth of new arterial 
collaterals (angiogenesis); in contrast, clinical improvement is more likely to be due to 
alterations in skeletal muscle metabolism, muscle hypertrophy, improvements in 
endothelial function, improved cellular or subcellular function, or altered gait.52-54 
 
A Cochrane Review in 2008 found 22 randomised controlled trials (involving a total of 
1,200 participants) of exercise regimens in patients with IC due to peripheral arterial 
disease.55  There was some variation in the exercise regimens used, however all 
recommended at least two sessions weekly of mostly supervised exercise.  Quality of 
the included trials was good, though the majority of trials were small with 20 to 49 
participants.  Compared with usual care or placebo, exercise significantly improved 
maximal walking time: mean difference (MD) 5.12 minutes (95% confidence interval 
(CI) 4.51 to 5.72;) with an overall improvement in walking ability of approximately 50% 
to 200%; exercise did not affect the ankle brachial index (ABI) (MD -0.01, 95% CI -0.05 
to 0.04). Walking distances were also significantly improved: pain-free walking distance 
MD 82.19 metres (95% CI 71.73 to 92.65) and maximum walking distance MD 113.20 
metres (95% CI 94.96 to 131.43). Improvements were seen for up to two years. 
 
However the Cochrane team did comment that the evidence was generally limited for 
exercise compared with more interventional treatments (most of the studies just 
compared exercise to best medical care).  A meta-analysis in 2011 compared 
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endovascular and non-invasive therapies in treatment of intermittent claudication and 
found that supervised exercise can provide similar results to endovascular therapy but 
that combining both approaches can have a synergistic effect.56  Greenhalgh et al 
showed a small but statistically significant improvement in ABI for those receiving 
supervised exercise alone vs supervised exercise plus endovascular therapy (0.74 vs 
0.90, p<0.05).57  However the study authors themselves questioned the 
representativeness of their patient population given the low recruitment rate and low 
rate of eligibility.  The issue should hopefully be more comprehensively addressed in a 
prospective, multicenter, randomized, controlled clinical trial to investigate the relative 
merits of exercise and endoluminal revascularisation that is currently underway.  The 
CLEVER (Claudication: Exercise Vs. Endoluminal Revascularization) study, is funded by 
the Heart, Lung, and Blood Institute of the National Institutes of Health and aims to 
evaluate the relative efficacy, safety, and health economic impact of four treatment 
strategies for people with aortoiliac peripheral arterial disease and claudication.  The 
treatment arms are: (1) optimal medical care (claudication pharmacotherapy); (2) 
primary stent placement; (3) supervised exercise rehabilitation; and (4) combined 
stenting with supervised exercise rehabilitation. It is a five-year study across 25 centres 
in the United States and is aiming to monitor approximately 250 patients for their 
responses to treatment during an 18-month follow-up period.58, 59 
 
Recruitment to the CLEVER study is now complete and final results are awaited.60  
Initial results from six months of follow up showed that supervised exercise resulted in 
superior treadmill walking performance compared to revascularisation with stenting, 
even for those with aortoiliac peripheral artery disease.  Interestingly however, 
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although disease-specific quality of life as assessed by WIQ and Peripheral Artery 
Questionnaire both improved compared to optimal medical therapy with either 
exercise or stenting, the extent of the improvement was greater in patients who had 
undergone stenting.61  Unfortunately their initial report does not cover analysis of the 
cohort that received both supervised exercise plus stenting. 
 
Intervention 
The main role for endovascular and surgical intervention is for patients with suspected 
proximal artery lesions (findings of buttock claudication, reduced/absent femoral 
pulse), ongoing symptoms limiting their quality of life despite non-invasive therapy, or 
for those with critical limb ischaemia.1, 53  In patients with milder disease a meta-
analysis of endovascular (angioplasty with/without stenting) and non-invasive 
therapies found no evidence that endovascular therapy alone provides improved 
outcome over supervised exercise alone.56  However it should be noted that the 
medical treatments in the studies that were considered were limited to advice on 
managing risk factors, aspirin (or clopidogrel in many cases) and occasionally smoking 
cessation advice.  There was no concerted attempt at either an exercise programme or 
consideration of other pharmacological therapy.  As mentioned above, the CLEVER 
study will hopefully provide a more comprehensive comparison between exercise and 
intervention and help guide clinicians as to the best time to pursue an interventional 
strategy. 
 
Restenosis by myointimal hyperplasia after peripheral arterial angioplasty or stenting is 
a major problem limiting its long-term efficiency and patency, and may lead to 
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recurrent symptoms.  There is some evidence that drug-eluting stents and balloons 
may be of benefit, but they are more expensive and cost-effectiveness has not yet 
been proven.62 
 
Over time the improvement in percutaneous experience and technology has led to a 
reduction in the need for open surgery.  It remains an option, but in many cases a 
percutaneous approach is feasible.  This has been summarised by Weinberg et al. in 
the flowchart shown in Figure 7.63 
 
 
Figure 7 – Approach for the patient who presents with claudication that interferes with their lifestyle  
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Pharmacological 
The three main pharmacological options for treatment of claudication symptoms that 
have received reasonably wide acceptance currently consist of cilostazol, pentoxifylline 
and naftidrofuryl.64  The comparative efficacy of these treatments compared to 
exercise (and atorvastatin) is shown in Figure 8.53 
 
 
Figure 8 – Improvement in walking distance with non-invasive interventions 
 
Cilostazol is a type III phosphodiesterase inhibitor with a mix of vasodilator, metabolic 
and antiplatelet activity.65, 66  It has shown consistent evidence of moderate benefit67 – 
usually in the region of 50-70m improvement on peak walking distance on treadmill.68  
The study by Regensteiner et al also looked at quality of life and found a significant 
overall improvement in both SF-36 and WIQ scores.  Patients receiving cilostazol did 
however consistently report an increased number of side-effects compared to those 
on placebo.69  These included diarrhoea, headache and palpitations.70  As it is in the 
same class as milrinone there is concern regarding a possible increase in mortality in 
patients with known congestive cardiac failure and its use is contra-indicated in this 
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group.  However in other patient groups to date there has been little evidence of any 
direct increase in mortality rates from cilostazol use.  Postmarketing surveillance in the 
United States, representing 70,430 patient-years of cilostazol exposure, showed 
minimal accounts of myocardial infarction, stroke, or death.71 
 
Pentoxifylline is a methylxanthine derivative that is known to increase erythrocyte 
deformability, inhibit neutrophil adhesion and activation and potentially lower plasma 
fibrinogen concentrations.  It was hoped these changes would improve claudication 
symptoms but the trial results have been extremely variable.  A recent Cochrane 
review of 23 studies (covering 2,816 participants) found great heterogeneity between 
the interventions and results.72  Only 17 of the studies compared pentoxifylline with 
placebo and in those the outcomes varied greatly, with the difference in percentage 
improvement in total walking distance ranging from 1.2% to 155.9%, and for pain-free 
walking distance the difference ranging from -33.8% to 73.9%.  They were unable to 
comment on the statistical significance of these changes due to lack of data, but found 
significant difference in ankle brachial pressure index after treatment with 
pentoxifylline.  The one positive for pentoxifylline is that it is generally well tolerated 
and therefore the current ACC/AHA PAD guidelines only recommend its use as an 
alternative in patients who are unable to tolerate cilostazol due to side-effects or in 
whom the use of the latter is contraindicated.52, 73 
 
Naftidrofuryl is a 5-hydroxytryptamine type 2 agonist and has been in widespread use 
for over 20 years in treating intermittent claudication, more so in Europe than North 
America.53  As well as reducing erythrocyte and platelet aggregation it is thought it 
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may have positive effects on muscle metabolism.74  A large number of trials have been 
carried out and in general it appears to be well tolerated and leads to a modest 
improvement in walking distance by around 26%.75-77  There is also some evidence on 
improved quality of life with naftidrofuryl, particularly in the domains of daily living, 
pain and social life.78, 79  Intravenous delivery has been evaluated but found only to 
show a trend to symptom improvement, with no statistically significant change.80 
 
However although these agents may have demonstrated clinical effectiveness to 
varying degrees, there are major concerns regarding cost-effectiveness.  A recent NICE 
technology appraisal recommended only naftidrofuryl as an option for treatment of 
intermittent claudication, with cilostazol and pentoxifylline falling into the “not 
recommended” category.  One of the main reasons for their decision was that these 
three drugs have no survival benefit – thus the Quality-Adjusted Life Year (QALY) 
calculations they carried out were mainly driven by the gain in mobility.  Given the 
small improvement in pain-free walking distance (around 5-30%, varying by study) that 
they provide and comparing to placebo, NICE calculated values of £50,700 (cilostazol), 
£6,070 (generic naftidrofuryl), £11,060 (branded naftidrofuryl) and £54,800 
(pentoxifylline) per QALY.25 
 
One further, naturally occurring, remedy that has been at times considered for PAD is 
garlic.  Medicinal use of garlic goes back to Egyptian times and there has been some 
evidence for the use of commercially available preparations in reducing atherosclerotic 
risk factors, especially cholesterol and platelet aggregation.  However a systematic 
review by the Cochrane Collaboration found only one suitable trial – this showed no 
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statistically significant change in walking distance.81  It is interesting that this topic was 
chosen by the Collaboration as an area that deserved a review to be carried out – this 
perhaps underscores the difficulties in finding effective treatments for PAD. 
 
Novel therapies 
In addition to the core approaches of exercise, intervention and pharmacology 
discussed above, there have been some interesting developments by way of biological 
therapies.  These mainly consist of utilising various angiogenic growth factors or 
autologous stem cells in an attempt to improve perfusion in areas of ischemia through 
the development of new blood vessels from pre-existing blood vessels. This process 
has been termed therapeutic angiogenesis and involves capillaries in the size range of 
100 to 300µm.82, 83  Due to the short half-life of most recombinant proteins the 
majority of clinical trials have focused on either stem cell or gene therapy approaches 
to provide longer-term delivery of these angiogenic growth factors. 
 
One group of patients in which there is particular interest in biological therapies is in 
those with critical limb ischaemia, especially as almost half of such patients are not 
candidates for open revascularization – either due to unsuitable anatomy, or 
associated comorbidities.84  Although some will be suitable for percutaneous 
intervention there remains a significant number in which no clear treatment options 
are available, thus ultimately leading to major amputation to control pain or infection.  
Medical therapy for CLI is limited to anti-platelets and secondary prevention (along 
with good wound care), making biological therapies all the more desirable.  In addition, 
the majority of patients with CLI have developed multilevel, complex vascular disease 
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with no one easy target to repair.  Biological therapies offer the potential to target all 
affected vessels simultaneously, potentially improving the overall treatment response. 
 
Stem cell therapy involves obtaining mononuclear cells from either the patient’s bone 
marrow or peripheral blood following subcutaneous injections of granulocyte colony-
stimulating factor for a number of days. These cells are then treated in a laboratory 
and injected (often at multiple sites) into the ischaemic lower limb(s).  The advantage 
of this technique is its relative simplicity and familiarity as a process from the field of 
Haematology.  There are also fewer concerns regarding ‘off-target’ angiogenesis 
compared to gene therapy.  Although there have been a number of positive small trial 
reports showing improvements in pain-free walking distance and reductions in 
amputation, a Cochrane review in 2011 felt that evidence from larger randomised 
controlled trials was needed in order to provide adequate statistical power to assess 
the role of intramuscular mononuclear cell implantation in patients with CLI. 
 
Gene therapy involves the insertion of genetic material into dysfunctional cells or 
tissues with the goal of curing the disease or alleviating its burden.85  Trials of gene 
therapy using a number of potential target factors have been carried out to date, with 
the main ones being: vascular endothelial growth factor (VEGF), hypoxia-inducible 
factor 1α, and fibroblast growth factor (FGF).  A summary of the major trials to date is 
shown in Figure 9 below.85 
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Figure 9 – Gene therapy trials 1996-2011 for PAD 
 
Unfortunately to date, despite promising Phase II results, the overall clinical results for 
gene therapy have not been positive.  The large TAMARIS trial of FGF (Phase III, 525 
patients) in patients with CLI found no difference between active and placebo 
treatment groups, with major amputation or death in 86 patients (33%) in the placebo 
group, and 96 (36%) in the active group (hazard ratio 1.11, 95% CI 0.83-1.49; p=0.48).86  
It was noted that this was in striking comparison to the positive results of the Phase II 
TALISMAN trial.87  When the results of these two trials were compared, the combined 
1-year major amputation and death rates in both treated groups were similar (27 per 
cent TALISMAN and 36 per cent TAMARIS).  Those reported in the control groups, 
however, differed markedly (52 per cent TALISMAN and 33 per cent TAMARIS).  It has 
therefore been postulated that the deemed efficacy of NV1FGF in TALISMAN was less 
due to therapeutic angiogenesis, and more the consequence of an abnormally high 
placebo endpoint rate not representative of the CLI population. Additionally, TAMARIS 
reported the use of current guidelines to ensure optimal medical management of 
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included patients, whereas there was no evidence of best medical treatment being 
used in TALISMAN, which may have further contributed to the discrepancy between 
the trials.85, 88 
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1.2 Oxidative stress 
An inevitable consequence of normal intracellular metabolism is the production of 
reactive oxygen species (ROS).  This term encompasses a wide range of molecules, 
including superoxide anions (O2
•-), hydroxyl radicals (•OH) and hydrogen peroxide 
(H2O2).  The key element these molecules have in common is the presence of an 
unpaired electron (often leading to the terminology ‘free radical’) and thus extremely 
high chemical reactivity.89  Oxygen as a molecule is especially susceptible to radical 
formation due to the presence of two unpaired electrons in separate orbitals in its 
outer shell.90 
 
In addition to endogenous sources from metabolism there are also a number of 
external stimuli that may lead to the generation of these molecules – for example 
exposure to ionising radiation, toxins (such as cigarette smoke), chemotherapeutic 
agents and ultraviolet light.  Cells exposed to abnormal environments such as 
hyperoxia or hypoxia also have much higher rates of ROS generation. 
 
Given the highly reactive nature of these molecules they have the ability to cause both 
direct cell damage and to interact with cell signalling pathways.  In combination this 
has the potential to lead to ageing, age-related diseases (including cancer) and cell 
death.91 
 
One of the best-known toxic effects of ROS is lipid peroxidation, involving the 
incorporation of a radical species (e.g., a hydroxyl radical) into the unsaturated fatty 
acid, as depicted in Figure 10.  This membrane lipid peroxidation may have a number 
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of deleterious effects, such as increased membrane rigidity, decreased activity of 
membrane-bound enzymes (such as sodium pumps), altered activity of membrane 
receptors and altered permeability.90 
 
 
Figure 10 – Illustration of lipid peroxidation (courtesy R Bowen) 
 
Mammalian physiology has therefore evolved both enzymatic and non-enzymatic 
mechanisms to manage and defend against these potentially damaging molecules, as 
outlined in Table 2.90, 92, 93  It has been noted that exercise appears to increase ROS, 
however training seems to reduce the oxidative stress of exercise, with trained 
athletes showing less evidence of lipid peroxidation and an enhanced defence system 
compared to untrained subjects.94 
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Enzymatic defences  
superoxide dismutases 
(SOD) 
 enzymes that catalyse the conversion of two 
superoxide molecules into hydrogen peroxide 
and oxygen (O2
•- + O2
•-  H2O2) 
 although hydrogen peroxide is still a ROS it is 
substantially less toxic that superoxide 
 SOD accelerate this detoxifying reaction roughly 
10,000-fold over the non-catalysed reaction 
 these enzymes depend on a bound manganese, 
copper or zinc for their antioxidant activity. In 
mammals, the manganese-containing enzyme is 
most abundant in mitochondria, while the zinc 
or copper forms predominant in cytoplasm 
 SOD are inducible enzymes - exposure of 
bacteria or vertebrate cells to higher 
concentrations of oxygen results in rapid 
increases in the concentration of SOD 
Catalase  found in peroxisomes in eukaryotic cells 
 degrades hydrogen peroxide to water and 
oxygen, hence completing the detoxification 
reaction started by SOD 
glutathione peroxidase  group of enzymes, the most abundant of which 
contain selenium 
 like catalase, these enzymes degrade hydrogen 
peroxide 
 also reduce organic peroxides to alcohols, 
providing another route for eliminating toxic 
oxidants 
Other enzymes  glutathione transferase, caeruloplasmin, 
hemoxygenase 
Non-enzymatic defences  
Vitamin A  obtained from the diet: green and yellow 
vegetables, dairy products, fruits and organ 
meats 
 within the body, vitamin A can be found as 
retinol, retinal and retinoic acid (all toxic at high 
concentrations and thus stored as long chain 
fatty esters/provitamin carotenoids in the liver, 
kidney and adipose tissue 
 antioxidant activity of vitamin A and 
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carotenoids is conferred by the hydrophobic 
chain of polyene units that can quench singlet 
oxygen , neutralize thiyl radicals and combine 
with and stabilize peroxyl radicals 93 
 some evidence that vitamin A deprivation leads 
to increased oxidative stress 92 
Vitamin C  a water-soluble antioxidant that can reduce 
radicals from a variety of sources 
 also appears to participate in recycling vitamin 
E radicals 
 under certain circumstances can also act as a 
pro-oxidant 
Vitamin E  the major lipid-soluble antioxidant 
 plays a vital role in protecting membranes from 
oxidative damage 
 primary activity is to trap peroxyl radicals in 
cellular membranes 
 some evidence of benefit of dietary 
supplementation in helping to reduce exercise-
induced muscle damage95 
Glutathione  possibly the most important intracellular 
defence against damage by reactive oxygen 
species 
 tripeptide composition (glutamyl-cysteinyl-
glycine) - the cysteine provides an exposed free 
sulphydryl group (SH) that is very reactive, 
providing an abundant target for radical attack 
 reaction with radicals oxidizes glutathione, but 
the reduced form is regenerated in a redox 
cycle involving glutathione reductase and the 
electron acceptor NADPH 
 some evidence that intravenous infusion may 
improved microcirculation and symptoms in 
PAD96 
Other (small molecules 
that function as anti-
oxidants) 
 bilirubin 
 uric acid (see section 1.3) 
 flavonoids and carotenoids 
Table 2 – Enzymatic and non-enzymatic defences against ROS 
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It should be noted however, as is often the case in physiology, that a balance must be 
struck when dealing with the regulation of ROS.  Too low a level of these molecules 
may lead to impairment in both cell proliferation and host defences – for example, 
generation of ROS by phagocytic cells is a key defence mechanism to combat infective 
organisms and release of ROS by platelets involved in wound repair acts as a chemo-
attractant for other platelets. 
 
This effect on platelets has been looked at in more detail by Davi et al.97  They 
examined lipid peroxidation and platelet activation in obese women and investigated 
whether this was modifiable after body weight reduction.  The study consisted of 
women who were in good general health with a normal medical history/physical 
examination save for a group of 44 participants who had android obesity (BMI >28; 
waist-to-hip ratio of ≥0.86) and 25 who had gynoid obesity (BMI >28; waist-to-hip ratio 
of ≤0.86).  A non-obese comparator group of 24 women all had a BMI lower than 25.  
To minimise confounding they excluded any women with a history or evidence of 
atherothrombotic diseases, diabetes mellitus, cigarette smoking, dyslipidaemia, 
current/recent pregnancy, arterial hypertension or were receiving hormone 
replacement therapy or aspirin. 
 
They found that android (abdominal) obesity was associated with a four-fold higher 
rate of thromboxane metabolite excretion (a marker of platelet activation) than 
measured in non-obese women, of a comparable magnitude to the changes found in 
association with type II diabetes mellitus, cigarette smoking and 
hypercholesterolaemia.  They postulated a biochemical link for this through increased 
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levels of F2-isoprostanes.  These bio-eicosanoids are produced from arachidonic acid 
through a process of non-enzymatic free radical-catalysed lipid peroxidation, thus 
giving a marker of the effects of oxidative stress (Figure 11).97 
 
 
Figure 11 – platelet activation through inflammation and nonenzymatic peroxidation of arachidonic acid 
 
The research team then proceeded to obtain evidence for a cause-and-effect 
relationship via a short-term diet-induced weight loss programme.  They found that a 
10% reduction in body weight obtained through a 12-week programme was associated 
with a reduction in thromboxane biosynthesis of over 50% and normalisation of this 
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non-invasive index of platelet activation.  It was also associated with statistically 
significant reductions in urinary 8-iso PGF2α isomer, a reflection of the in-vivo 
formation of F2-isoprostanes.  The study was however self-selecting with no 
randomisation to weight loss vs maintenance (albeit there were some who failed to 
lose weight and had no reduction in their biomarkers) and had a small sample size.  It 
does however raise interesting questions around the role of central obesity in platelet 
activation and potentially an insight into the benefits of reducing lipid peroxidation 
through other routes in addition to weight loss. 
 
An overview of both the sources of ROS and the homeostatic balance required to 
maintain appropriate levels is shown in the illustration by Finkel & Holbrook in Figure 
12.91 
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Figure 12 – Reactive oxygen species (Finkel/Holbrook) 
 
As can be seen in the figure, there are a number of cytosolic enzyme systems that 
contribute to oxidative stress.  Their relation to the purine degradation pathway will be 
discussed further later, in particular the role of NADPH oxidases (a superoxide-
generating system that was first described in the neutrophil).91 
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1.3 Uric acid 
Uric acid (also referred to interchangeably as urate) is the metabolic breakdown 
product of purine nucleotides, consisting of carbon, hydrogen, nitrogen and oxygen 
with the formula C5H4N4O3 and the structure shown in Figure 13.
98 
 
Figure 13 – Structure of uric acid 
 
The most common medical implication of uric acid is the formation of monosodium 
urate crystals in joints leading to gout.  Uric acid is produced mainly in the liver and to 
a lesser extent in the small intestine.  Its production depends on the balance between 
purine ingestion, de-novo synthesis in cells, recycling, and the degradation function of 
xanthine oxidase at the distal end of the purine pathway (see Figure 16).99 
 
Around 70% of excretion occurs via the kidneys therefore impairment of renal function 
is one possible cause for raised serum levels.  Human beings and higher primates do 
not have the enzyme uricase that degrades uric acid to the highly soluble allantoin.100  
Therefore much higher urate levels are found in humans than are those of most non-
primate mammals, fish, and amphibians that possess uricase.  Consequently, the 
physiological concentration of urate in humans is close to its limit of solubility.99  Thus 
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diuretic drugs (especially thiazides) may interfere with the renal excretion of urate, 
thus increasing urate levels and raising the chance of crystal formation – high intake of 
purine-rich foods may further compound matters. 
 
Although it has an undisputed role in gout, uric acid has a more complex role when it 
comes to the cardiovascular system.  There is consistent evidence of increased levels 
being associated with cardiovascular disease however this correlation has not always 
been independent of other risk factors.101  Multiple studies have confirmed this 
association between baseline hyperuricaemia and cardiovascular disease, however a 
causal link has not clearly been proven.102-105  Much of the data seems to demonstrate 
more of a linkage with other risk factors such as hypertension, dyslipidaemia and 
impaired glucose metabolism.104 
 
However as mentioned in section 1.2, the uric acid molecule itself shows antioxidant 
behaviour – the majority of this role seems to be a scavenging ability with regards to 
peroxynitrite.106  Peroxynitrite (formula ONOO-) is formed by the reaction of nitric 
oxide (NO) with superoxide (O2
•-).  The resulting molecule is itself not technically a free 
radical, as the unpaired electrons on the constituent superoxide and nitric oxide free 
radicals have each combined to form a new chemical bond, but it chemically remains a 
powerful oxidant that can damage a wide array of molecules in cells, including DNA 
and proteins.107, 108  This appears to have particular relevance when considering the 
disease of multiple sclerosis (MS). 
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MS is a chronic T-cell mediated inflammatory demyelinating disease – as a result there 
has been much interest in the role that reactive oxygen and nitrogen species play in 
inflammation, demyelination and axonal injury.109  There has been some interesting 
evidence to date of a positive role for uric acid in treating symptoms in animal models 
and of possibly stabilising lesion progression in humans through the use of inosine to 
raise uric acid levels.110, 111  In addition, statistical evaluation of more than 20 million 
patient records for the incidence of MS and gout (hyperuricaemic) revealed that the 
two diseases are almost mutually exclusive, raising the possibility that hyperuricaemia 
may protect against MS.106 
 
It is therefore unclear as to whether the increased levels of uric acid in diseases 
associated with oxidative stress are a cause of harm or instead a protective response.  
There is also the potential that uric acid may be neither good nor bad itself, but instead 
be an indicator of the activity of xanthine oxidase activity, itself an important source of 
reactive oxygen species, as will be discussed in the next section.104 
 
There an interesting gender split with regards uric acid.  Analysis of data from the 
Framingham study showed that with increasing age there was a minimal change in uric 
acid levels for men, yet a gradual increase from the fourth to seventh decade in 
women, as illustrated in Figure 14.104  This may well be related to the role of 
oestrogen, which has a uricosuric effect.112 
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Figure 14 – Mean serum uric acid level by sex and 5-year age group 
 
Most studies have not found a positive independent association between serum uric 
acid level and risk of cardiovascular disease in men.  Those that have done so failed to 
account for confounders such as altered glucose metabolism, weight and diuretic use.  
In Framingham data this initially showed a strong and graded association between 
baseline uric acid and increased CV risk, but this risk was substantially reduced after 
adjusting for age and eliminated completely in a multivariate model.104 
 
There has been some discussion around the potential role of uric acid in the metabolic 
syndrome.  Potential mechanisms for this include the impact on endothelial function 
from hyperuricaemia (leading to reduced glucose uptake in skeletal muscle) and the 
inflammatory and oxidative changes uric acid appears to induce in adipocytes.  In 
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hypertension animal models, hypertension appeared to be due to uric acid–mediated 
renal vasoconstriction resulting from a reduction in endothelial levels of nitric oxide, 
with activation of the renin–angiotensin system.113  Consistent with these 
observations, elevated uric acid levels in humans also correlate with endothelial 
dysfunction and increases in plasma renin activity.103 
 
In conclusion there is an association between uric acid and CV disease, however when 
properly analysed to take account of age, diuretic use and traditional CV risk factors 
this appears to be more a marker than a causative agent in and of itself.  However the 
purine degradation pathway (which eventually produces uric acid) has a number of 
interesting components that probably play a role in oxidative stress and thus 
manipulation of the pathway may well be of therapeutic importance. 
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1.4 Allopurinol 
1.4.1 History, pharmacokinetics, side-effects and alternatives 
Given the association between uric acid and disease states as well as a potential role in 
oxidative stress there has understandably been great interest in whether reducing uric 
acid levels may have clinical utility.  The main drug used to date for this role has been 
allopurinol. 
 
As can be seen in Figure 15 below, allopurinol is a purine analogue (the similarities to 
uric acid can be seen by comparison to Figure 13) – a structural isomer of 
hypoxanthine and an inhibitor of xanthine oxidase, thus decreasing uric acid formation 
through the purine degradation pathway, as illustrated in Figure 16.114, 115 
 
 
Figure 15 – Structure of allopurinol 
 
Allopurinol was first synthesised in 1955 by Robins, who was investigating the 
possibility of developing new compounds that were isomeric with various biologically 
active purines in the hope that new anti-neoplastic agents might be discovered.116  
Although allopurinol itself was not anti-neoplastic, it was subsequently found by Elion 
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and Hitchings to inhibit the breakdown of one of the other purines, the 
chemotherapeutic agent mercaptopurine, leading to higher serum levels.117  However 
it quickly became apparent that whilst allopurinol reduced the effective dose of 
mercaptopurine required in patients with chronic granulocytic leukaemia (in whom it 
was first tested), it did not appear to increase its therapeutic effectiveness.  What was 
discovered though was that the hyperuricaemia and hyperuricosuria produced by 
tumour lysis syndrome aggressive chemotherapy in some patients with neoplastic 
disease could be averted and this new compound was then used almost exclusively for 
that purpose. 118-120 
 
However outwith oncology, allopurinol quickly became established in the main role it 
still occupies today – that of lowering uric acid levels to reduce the frequency of gout 
attacks. 
 
Allopurinol interferes with the catabolism of purines by inhibiting the activity of the 
enzyme xanthine oxidoreductase (XOR).  XOR is a complex molybdoflavoenzyme that, 
thanks to its ready availability in cows’ milk (where it forms a major component of the 
milk fat globule membrane), has been known about for well over a century and in an 
essentially pure form for over 70 years.  The cellular distribution of XOR is somewhat 
specialised, with relatively high concentrations being found in epithelial and 
endothelial cells.  At first glance this would not seem consistent with its role solely as a 
housekeeping enzyme of purine catabolism and thus the relevance of it to other 
physiological functions has been sought – in particular the role it may play in 
ischaemia-reperfusion injury.121 
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XOR exists in two interconvertible forms in mammals, xanthine oxidase (XO) and 
xanthine dehydrogenase (XDH).  It is found in various organs of the body although the 
highest levels of activity being found in the liver and intestine.  Overall in vivo there is 
about an 80/20 split in favour of XDH, however due to endogenous serum proteases 
the majority of the XOR found in the circulation is in the XO form and thus commonly 
in the literature reference is made to XO rather than XOR.121-124 
 
XO which has been released into the circulation has been observed to bind to a 
number of endothelia, including that of the vasculature.  When bound to these 
endothelia it continues to exhibit normal reactivity and continues to produce 
superoxide, resulting in oxidative stress and endothelial dysfunction.125  There is also 
some experimental evidence (albeit in mice) that nitric oxide inhibits XO activity.126  
Therefore in a situation where there is reduced NO, such as atherosclerosis, there may 
be increased XO activity and thus increased superoxide production which in turn then 
inhibits NO synthase, further decreasing NO bioactivity.  Externally blocking this cycle 
via a XOR inhibitor may help break the downward spiral and help restore more normal 
endothelial function. 
 
A small study by Spiekermann et al looked at both ex-vivo and in-vivo XO activity in 
patients with CAD compared to those without.  The ex-vivo arm of the study (using 
post-mortem samples) demonstrated that in patients with CAD, XO and NADPH 
oxidase activity in the coronary arteries was increased compared with control subjects 
without atherosclerotic disease.  In vivo, endothelial XO activity was increased in 
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patients with CAD compared with age-matched controls and found to be inversely 
related to endothelium-dependent vasodilation, suggesting that increased activity of 
XO was potentially contributing to endothelial dysfunction in patients with CAD.  They 
found that XO-driven O2
•- formation was abolished by oxypurinol, whereas NADP-
mediated O2
•- formation remained unaffected.127 
 
The XO and XDH forms can be interconverted reversibly via sulphide reagents, or 
irreversibly (XDH to XO) by proteolysis.  XO reduces only oxygen, whereas XDH is able 
to reduce either oxygen or NAD+, but has a greater affinity for the latter.128, 129 
 
Figure 16 provides a schematic representation of XOR-catalysed oxidation of xanthine 
and hypoxanthine at the molybdenum site, and of NADH, NAD, or molecular oxygen at 
the FAD site.128  It can be seen that a by-product of the production of uric acid is the 
formation of ROS.130 
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Figure 16 – Purine synthesis, salvation and degradation 
 
As mentioned above, XOR was initially isolated from the bovine milk fat globule 
membrane.  The enzyme can also be isolated from human breast milk, although due to 
its low molybdenum content the activity level is relatively low on the Mo binding sites.  
NADH activity on the other hand (which uses the FAD site) is very similar.121 
 
As well as blocking XOR, allopurinol is also a substrate for it – the deriving metabolite, 
oxypurinol is a potent inhibitor of XOR itself and indeed may be considered responsible 
for much of the pharmacological effect.131  The relative structures of allopurinol and 
oxypurinol are shown in Figure 17.132 
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Figure 17 – Chemical structure of allopurinol and oxypurinol 
 
Oral bioavailability of allopurinol is good (67-90%), with peak plasma concentration 
being reached within an hour.  It is then rapidly metabolised in the liver by oxidation to 
oxypurinol within a few hours of ingestion.  The mean elimination half-life of 
allopurinol is around an hour and oxypurinol around 18-40 hours.  The renal clearance 
of both allopurinol and oxypurinol is lowered in elderly versus young subjects. 115, 132, 
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Interestingly in studies of patients with xanthinuria (a rare genetic disorder where XOR 
deficiency leads to accumulation of xanthine) it appears that the enzyme aldehyde 
oxidase may also have a role to play in the conversion of allopurinol to oxypurinol.134 
 
Allopurinol is generally well-tolerated as a drug, with the most frequently noted side-
effects being gastrointestinal upset and skin rash.  Other less common adverse effects 
include fever, jaundice, impaired renal function, leukopaenia, and thrombocytopaenia. 
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The more serious adverse effects tend to occur at higher doses and in patients with 
renal impairment.  Neither allopurinol nor oxypurinol are significantly plasma protein 
bound, with both being renally excreted therefore it has been suggested that adverse 
effects of allopurinol are more frequent when there is renal insufficiency, however in 
clinical practice it appears that appropriate dose adjustment in patients with renal 
impairment is sufficient to mitigate against this being a major problem.135, 136  There is 
some evidence that in patients where a reduced dose is insufficient to lower uric acid 
levels significantly then it is probably safe to cautiously proceed to higher doses.137 
 
The most concerning potential side effect is that of Stevens-Johnson syndrome (SJS) as 
ultimately, in very rare cases, this may be fatal.118, 138, 139  Allopurinol is the most 
common cause of SJS and toxic epidermal necrolysis in Europe.140  However 
interestingly some recent research suggests that rather than this rare reaction being a 
dose-independent unpredictable event (what would conventionally be thought of as a 
‘type B reaction’), this may in fact be primarily driven by an oxypurinol-specific T cell 
response in a dose-dependent manner – something that has been found to be more 
marked in the presence of the HLA-B*58:01 allele.132 
 
With regards to interaction with other drugs, the main concern is the reduction in 
metabolic clearance of mercaptopurine and azathioprine.  There is some interaction 
with warfarin but with ongoing INR monitoring the anti-coagulant dosing is easily 
adjusted to take account of this.  Overall clinical experience suggests patients tolerate 
the drug well, with only 1.8% of patients in a large drug monitoring study experiencing 
unintended/undesired effects.118 
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An alternative to allopurinol (currently only approved in the European Union) is 
febuxostat.141  This is a novel non-purine xanthine oxidase inhibitor with approved 
doses of 80 mg per day and 120 mg per day.  Dose adjustment is not necessary in 
patients with mild renal failure. Side-effects of febuxostat include raised liver enzyme 
activity and a small increase in the rate of serious cardiovascular events, in comparison 
to allopurinol, which therefore precludes its current use in patients with ischaemic or 
congestive heart failure.99 
 
In a double-blind trial comparing febuxostat and a fixed dose of allopurinol (300mg per 
day) there was shown to be a greater reduction in uric acid levels with febuxostat but 
no significant difference in either gout flares or tophus area between the groups.142  
 
Oxypurinol itself is available in some countries as a treatment option for gout, however 
given the excellent bioavailability of allopurinol, regardless of formulation, it has not 
gained widespread acceptance in that role.100, 143, 144 
 
In section 1.2 the importance of reactive oxygen species was discussed.  With regards 
to XOR, superoxide generation occurs in the presence of hypoxia when the enzyme 
transfers electrons to molecular oxygen rather than to NAD+ during the formation of 
uric acid, thus contributing to oxidative stress.101  It has been postulated that whilst 
this may implicate XOR to an extent in ischemia-reperfusion injury, it may also be the 
case that XOR-derived ROS and reactive nitrogen species (RNS) play a role in innate 
immunity, specifically in the inflammatory response and in anti-microbial defence of 
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the gastrointestinal tract – something that would fit with the levels of activity found in 
different tissues of the body.121, 128 
 
1.4.2 Evidence of utility in cardiovascular disease 
Given the role of XOR in superoxide formation there has been a great deal of interest 
in whether blockade of XOR activity via allopurinol is of clinical benefit.130 
 
There is a logical potential pathophysiological mechanism for why this may be of 
benefit, particularly in ischaemic tissues.  Firstly, molecular oxygen is a substrate for 
xanthine oxidase which consumes it and converts it into superoxide anions, hence 
depriving ischaemic tissue of vital molecular oxygen.  Secondly, this “O2 depriving” 
effect of XO is made worse by the fact that XO activity is upregulated in ischaemic 
tissue, hence initiating a vicious cycle whereby ischaemic tissue is deprived of oxygen 
even more.145, 146 
 
The initial focus on oxygen was with regard to ischaemia-reperfusion injury, where 
oxygen is first switched off then suddenly available in abundance.  In the early 1980s 
Granger et al first hypothesised a key role for XOR in this injury process.  They 
postulated that during ischemia the energy status of the cell falls and transmembrane 
gradients break down. This leads to a rise in levels of intracellular calcium, which 
activates proteases that convert XDH, predominant in vivo, into XO.147  Concomitantly, 
purines are catabolised and hypoxanthine accumulates.  On reperfusion, oxygen is 
again available and, in the presence of XO and hypoxanthine, is reduced to hydrogen 
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peroxide and superoxide. These ROS interact to generate destructive agents such as 
hydroxyl anions and cause tissue damage.148, 149 
 
Heart failure 
At the turn of the millennium much of the research in the area of allopurinol and heart 
failure focussed on animal studies.  There were promising results, both in rats and 
dogs, showing improved myocardial contractility (possibly in part due to a Ca2+-
sensitising property of XO inhibitors) and decreased myocardial oxygen 
consumption.150-153  There was also a suggestion that both NOS and XOR signalling 
systems participate in the regulation of myocardial mechanical efficiency and that up-
regulation of XOR relative to NOS contributes to mechano-energetic uncoupling in 
heart failure (particularly in the context of beta-adrenergic stimulation) and thus an 
opportunity for allopurinol to improve function.154-156 
 
Research progressed to look at humans and Cappola et al found that intra-coronary 
injection of allopurinol in patients with idiopathic cardiomyopathy led to a 16% 
reduction (±5%, p<0.01) in myocardial oxygen consumption and an almost one-fifth 
improvement in myocardial efficiency.157 
 
In 2002 Farquharson et al showed in a small randomised, placebo-controlled, double-
blind crossover study that allopurinol improves endothelial dysfunction in chronic 
heart failure. This raised the possibility that allopurinol might reduce cardiovascular 
events and even improve exercise capacity in chronic heart failure.158 
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By the mid-2000s further clinical trials had been undertaken, the largest of which was 
the OPT-CHF study by Hare et al, looking at oxypurinol in patients with heart failure.159-
161 
 
The groundwork for OPT-CHF had been laid by the EXOTIC-EF study, which used 
intravenous oxypurinol.162  It had shown a statistically significant improvement in left 
ventricular ejection fraction (LVEF) of almost a fifth, however it was a small open-label 
trial. 
 
Around the same time the La Plata study reported.  It was a month-long study of 60 
patients with NYHA Class II-III heart failure, however by comparison it was a 
randomised, placebo-controlled double-blind trial.  The main outcome of LVEF showed 
a 5% improvement in the active treatment group, although this did not reach statistical 
significance (p<0.08).  Exclusion of those with an LVEF of >40% at baseline gave a 
statistically significant 7% increase in LVEF in the active arm (p<0.02), however it did 
reduce the numbers in the study by a third.163  The efficacy of their dosing could also 
be questioned, with a reduction in uric acid level of only around 20%. 
 
OPT-CHF by comparison was a much larger multicentre, randomised, double-blind, 
placebo-controlled, parallel group study of oxypurinol, this time involving just over 400 
patients with a treatment period of six months.  Uric acid reduction this time was 
marginally better at 25% in the active group however it did not produce a clinical 
improvement in the overall study population of patients with moderate-severe (NYHA 
III-IV) heart failure.  In post-hoc analysis they did however find that those with higher 
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baseline uric acid levels responded better to oxypurinol both by way of percentage 
reduction in uric acid levels and also by way of clinical improvement.  Again one does 
wonder whether the selected dose of oxypurinol was too low given that reductions in 
uric acid of almost double this level have previously been achieved using allopurinol.164  
Under-dosing is a common issue, with some studies looking for improvements in 
function after just a single dose rather than achieving a larger reduction in uric acid 
over a sustained period.165  Importantly George et al (2006) showed that allopurinol 
had a steep dose-response curve in that 600mg of allopurinol produced twice the 
benefit of 300mg with regards endothelial function.166  This again underscores the 
importance of getting the dose right. 
 
Hypertension 
As already mentioned in section 1.3, the Framingham Study provides useful 
information about uric acid levels in a large and well-monitored population.  
Sundström and colleagues made use of the data to investigate the relationship with 
hypertension.167  They found that by the four-year follow-up point 13.8% of the 3,329 
participants had developed hypertension and 36.1% had progressed to a higher stage 
of blood pressure.  In multivariable analyses adjusting for age, sex, body mass index, 
diabetes, smoking, alcohol intake, serum creatinine, proteinuria, glomerular filtration 
rate, baseline BP, and interim weight change, a 1 SD higher serum UA was associated 
with an OR of 1.17 (95% CI 1.02 to 1.33) for developing hypertension, and an OR of 
1.11 (95% C, 1.01 to 1.23) for BP progression.  The serum uric acid level therefore 
appeared to be an independent predictor of hypertension incidence and BP 
progression in the study population. 
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In the same year Alper and colleagues published their analysis of the effect of uric acid 
levels in children and adolescents participating in the Bogalusa Heart Study.168  They 
also carried out a multivariate regression analysis and found that elevated serum uric 
acid levels in childhood are associated with increased blood pressure both in childhood 
and higher blood pressure levels that persist into adulthood. 
 
These data then naturally raised the question as to whether therapy aimed at lowering 
uric acid levels (by way of treatment with allopurinol) would be of benefit.  Agarwal 
attempted to address this question in their meta-analysis of studies to date.169  
Unfortunately the small number of studies available in this area represented quite a 
heterogenous group, with widely varying dosage and inclusion/exclusion criteria.  The 
ages of participants alone was varied, with mean ages ranging from 15 to 72 years.170  
The results did however show that there was a small, but statistically significant, 
reduction in both systolic (-3.3mmHg, 95% CI -5.3 to -1.4mmHg) and diastolic  
(-1.3mmHg, 95% CI -2.5 to 0.1mmHg) blood pressure readings.  Some subsequent 
discussion of the meta-analysis challenged the lack of large RCTs and the strength of 
recommendation being offered, however the original authors did highlight that the 
role of allopurinol being envisaged was very much one of a later-stage agent and that 
further RCTs would be required prior to full recommendation in that regard – however 
in patients already at increased risk of gout (e.g., through use of diuretics), they felt it 
may be information that was of interest to clinicians when considering their 
prescribing strategy.171, 172 
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Endothelial function 
As mentioned in section 1.2, the vascular endothelium is a complex structure that is 
vulnerable to damage from ROS, in particular through inactivation of NO.173, 174  Given 
the mechanistic benefits allopurinol may be able to bring in reversing this trend and 
the previous in vitro studies showing positive effects, there have been a number of 
studies looking at the potential clinical benefits of this approach to improving 
endothelial function.175, 176 
 
Initially hyperuricaemia itself was viewed as being a potential causative agent in 
vascular stress, in particular due to the impaired flow-mediated dilatation in 
hyperuricaemic patients.177, 178 
 
However more recently there has been emerging evidence that the benefit of 
allopurinol is more through its effect on reducing vascular oxidative stress.  George and 
colleagues showed this by comparing uric acid lowering by way of allopurinol 
compared to probenecid.  Despite very similar reductions in uric acid levels (44% vs 
46% respectively), there was no effect on endothelial-dependent vasodilatation in the 
probenecid group, compared to a 52% improvement in the allopurinol group.166 
 
This positive effect of allopurinol independent of uric acid lowering has also been 
shown more recently by Jalal et al.  They examined the data of over a hundred healthy 
volunteers participating in a community-based study in Boulder, Colorado, USA.  They 
all had endothelial-dependent/independent dilatation examined by way of flow-
mediated dilatation (FMD) and brachial artery response to GTN spray.  They found that 
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individuals with the highest quartile of uric acid tended to be older and more likely to 
be male compared to those in the lowest quartile.  They found no significant change in 
endothelial-dependent dilatation (via FMD) across increasing uric acid levels. They 
found a non-significant tendency for endothelial-independent dilatation (via GTN) to 
reduce slightly with increasing uric acid levels, along with a significant increase in CRP 
levels and a non-significant trend to increase in Oxidised LDL levels.179 
 
Endothelial function has been assessed in a number of other co-existent disease 
processes.  In hyperuricaemic patients with heart failure, XO inhibition with allopurinol 
was shown to improve peripheral vasodilator capacity and blood flow both locally and 
systemically.180  It has also been shown to improve forearm blood-flow in patients with 
type II diabetes mellitus.181  In patients with CAD both oxypurinol and allopurinol have 
been shown to be beneficial in improving measures of peripheral endothelial 
function.182, 183  However there have been some slightly mixed reports when solely 
hypercholesterolaemia is considered, with Cardillo et al finding an improvement (albeit 
not normalisation) yet O’Driscoll et al finding no change.184, 185 
 
What about patients without overt cardiovascular disease?  Guthikonda and 
colleagues looked at a group that would be expected to have high levels of ROS-
mediated endothelial damage – smokers.  Their study was a randomised, crossover 
design with 14 smokers and 14 age/sex-matched non-smokers, all of whom had no 
other risk factors for atherosclerosis.  They also only looked at a single-dose of 
allopurinol rather than long-term dosing and the study was only single-blinded.  They 
did however find evidence of endothelial dysfunction, in that the responses to intra-
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arterial bradykinin and acetylcholine (both endothelium-dependent dilators) were 
impaired in smokers compared to non-smokers.  Administration of a single dose of 
allopurinol brought the response from smokers up to non-smoker levels with no 
change in the latter group.  Their data suggested that stimulated NO production was 
reduced in smokers and improved by administration of allopurinol – it was theorised 
that this was most likely from reduced superoxide production due to XO blockade.186 
 
Diabetes 
Patients with diabetes have a much higher prevalence of LVH than non-diabetics, 
regardless of whether or not they have concomitant hypertension.  Those with LVH 
and hypertension also have a blunted response to treatment with anti-hypertensive 
agents.187 
 
There is evidence that treatment with allopurinol produces a reduction in LV mass in 
various animal models and in those with coronary artery and chronic kidney 
disease.188, 189  It has recently also been shown to be beneficial in patients with 
diabetes mellitus, even although the magnitude of reduction was not as big as in anti-
hypertensive trials this may still be beneficial in the long term.  In other words, 
allopurinol acts on the BP-independent contribution to LV mass.  This reduction in LV 
mass was thought to be due to the reduction in oxidative stress-mediated myocardial 
hypertrophy.190 
 
There is also evidence of dysfunctional endothelial NO synthase function in patients 
with diabetes that led to increased vascular superoxide production.191  It has been 
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shown that treatment with allopurinol in patients with diabetes has the ability to 
restore endothelial function in these situations.181 
 
Ischaemic heart disease 
As discussed above, there is evidence of the benefit of allopurinol in patients with IHD 
by way of LVH regression.188  There is also evidence that even in patients already on 
contemporary, evidence-based treatment for IHD endogenous xanthine oxidase 
continues to generate vascular oxidative stress and widespread endothelial 
dysfunction. Treatment with allopurinol in these patients led to a significant 
improvement in acetylcholine-mediated vasodilatation on allopurinol compared with 
placebo, raising the prospect that high dose allopurinol (or its active metabolite, 
oxypurinol) might reduce future atherothrombotic events in CAD over and above the 
current therapies.182, 183, 192 
 
However the question then arises – do these improvements in endothelial function 
and oxidative stress translate into clinical improvement for patients with angina?  
Noman et al showed that treatment with high-dose allopurinol significantly prolonged 
the time to ST segment depression, the total exercise time, and the time to angina in 
patients with chronic stable angina during a standard exercise test.193  This suggests 
that endogenous xanthine oxidase activity contributes in some way to exercise-
induced myocardial ischaemia.  The previously discussed mechanisms of improved 
myocardial contractility and reduce oxygen consumption in the case of patients heart 
failure are additional mechanisms that are likely to contribute to its efficacy in IHD and 
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open up the potential of it being used as an add-on treatment to conventional 
therapy.194, 195 
 
In addition, Rekhraj et al (2013) showed that allopurinol reduced LV end systolic 
volume and LV afterload (as measured by augmentation index) in patients with 
ischaemic heart disease, which suggests that offloading the LV may be another 
mechanism contributing to the anti-ischaemic effect of allopurinol in angina 
pectoris.188  This possibility is highly relevant to the work in this thesis since this 
particular effect on LV afterload would produce an anti-ischaemic effect on the heart 
but not an anti-ischaemic effect in PAD. 
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1.5 Summary 
Peripheral arterial disease is an important issue that affects a large number of patients 
with risks of significant morbidity and mortality.  At present there are limited 
treatment options available to patients, particularly when compared to other 
comparable vascular diseases such as angina. 
 
Smoking cessation and modification of risk factors remains the cornerstone of therapy 
in PAD.  In those with severe symptoms intervention by way of angioplasty or surgery 
are viable options with varying success in individual patients.  However the majority of 
patients are limited to medical therapy, which in itself mainly acts only to modify risk 
factors rather than treat symptoms.  The small number of drugs are available to treat 
symptoms are expensive and have limited efficacy. 
 
An inevitable consequence of normal intracellular metabolism is the production of 
reactive oxygen species.  Of particular relevance here is the production of hydrogen 
peroxide and superoxide.  This happens as a by-product of the formation of uric acid 
by XOR and thus blockade of this process may be beneficial in reducing the endothelial 
dysfunction caused by ROS. 
 
Allopurinol is a well-established drug that is highly effective in blocking XOR and 
reducing uric acid levels.  It is a mainstay of the preventive treatment of gout and has 
shown some promise in a number of cardiovascular conditions. 
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This cardiovascular improvement is likely to be through its effect on oxidative stress 
and NO in ischaemic tissue and an oxygen-sparing effect in tissues – there is therefore 
an important research question to be answered which is whether allopurinol will exert 
an anti-ischaemic effect in PAD.  This is a key question given that allopurinol is anti-
ischaemic in an analogous group of patients (those with angina pectoris). 
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2 Methods 
2.1 Study design 
This study was a randomised, double-blind parallel-group placebo-controlled clinical 
trial, run in accordance with the Declaration of Helsinki and The Medicines for Human 
Use (Clinical Trials) (Amendment) Regulations 2006. 
 
The aim of the study was to examine whether high dose allopurinol prolongs exercise 
duration in patients with PAD. 
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2.2 Approvals 
Sponsor approval 
Reference: 2009CV16 
Submitted: 9th April 2010 
Sponsorship was confirmed and permission to apply for CTA granted on the 12th May 
2010. 
 
Ethical approval 
Reference: 10/MRE00/51 
Submitted: 31st May 2010 
An initial favourable reply from Scotland A REC was received on the 28th June 2010 
with minor amendments requested.  Amendments were submitted on the 7th July 
2010 and final approval received on the 19th July 2010. 
 
NHS R&D approval 
Reference: 2009CV16 
Submitted: 9th July 2010 
Approval was received on the 4th February 2011 (once MHRA approval had been 
received). 
 
  
81 
 
MHRA approval 
Reference: 21726/0273/001-0001 
Submitted: 17th June 2010 
 
This took a number of months to process – the timetable of events was as described in 
Table 3 below. 
 
Date Progress 
17th June 2010 Initial submission made. 
13th August 2010 Initial MHRA reply – non-approval on 
pharmaceutical points, wished to know the amount 
of lactose in the placebo and how the placebo 
capsules were being tested to confirm the absence 
of allopurinol. 
23rd August 2010 Reply sent to MHRA including detailed note from 
Tayside Pharmaceutical following their telephone 
discussions. 
8th September 2010 Reply from MHRA – accept the changes but still 
wish to know the precise amount of lactose and 
require a test batch to be made to determine this. 
18th November 2010 Test batch manufactured and revised IMP dossier 
sent to MHRA. 
14th January 2011 Full MHRA approval received. 
Table 3 – MHRA application timetable 
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Trial registries 
ISRCTN: the study was registered and allocated reference ISRCTN01772998. 
ClinicalTrials.gov: the study was registered and allocated reference NCT01147705. 
EudraCT: the study was registered and allocated reference 2010-020662-23 
 
Funding 
An application for funding was made to the British Heart Foundation on 12th August 
2009.  This was considered by their Fellowships Committee and an award covering the 
full costs of the study was confirmed on 27th January 2010 – BHF Clinical Research 
Training Fellowship FS/10/014/28079. 
 
The overall timeline for study setup is as show in Figure 18. 
 
 
 
 
 
 
 
 
 
Figure 18 – Study timeline 
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2.3 Inclusion/exclusion criteria 
The inclusion/exclusion criteria were as noted in Table 4 below. 
Inclusion  men and women age 35-85 years suffering from PAD 
 PAD defined as: 
o claudication defined as leg pain on walking and disappearing 
within 10 minutes on standing and of presumed 
atherosclerotic origin and 
o an ankle brachial pressure index (ABPI) of <0.90 on the 
worst leg at rest 
 stable disease by having a reproducible pain free walking distance 
on two consecutive treadmill tests, i.e., less than 25% variance 
 the reason for termination of the test must be claudication pain 
only 
Exclusion  rest pain 
 childbearing potential not taking adequate contraceptive measures 
 heart failure or any other exercise limiting cardiac disease 
 BP >180/100 mmHg 
 renal or liver disease 
 malignancy 
 already on allopurinol or had an adverse reaction to it 
 recent marked change in symptoms or recent (in the last six 
months) intervention for PAD 
 receiving treatment with either 6-mercaptopurine, azathioprine, 
warfarin, or theophylline 
Table 4 – Inclusion/exclusion criteria 
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2.4 Cohort size & power calculation 
A meta-analysis of exercise treatment trials in PAD and several drug trials was initially 
used to guide the required power for the study.  In randomised trials in PAD, the SD 
tends to be around 30 metres.49, 196-199 In drug treatment trials, the time to 
claudication usually increases by around 30 metres (on average 30% more than 
placebo).49, 196-200  A 30 metre improvement is thought to make a clinically significant 
difference in PAD.  If it is assumed a 30 metres improvement with a 30 metres SD, then 
only 42 subjects total in a parallel group study would be required to demonstrate a 30 
metre improvement over placebo (for 90% power at p<0.05).  However to allow for 
drop-outs, 50 PAD subjects were enrolled in this study. 
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2.5 Recruitment 
2.5.1 Intermittent claudication clinic 
With the exception of one patient (who directly approached AJR after seeing the trial 
listed on the ClinicalTrials.gov website), all patients in the study were recruited 
following their attendance at the Intermittent Claudication Clinic at Ninewells Hospital, 
Dundee.  This clinic is run by a Vascular Specialist Nurse (Gill Crowe) – some patients 
were informed of the study by GC and their details passed to AJR to contact them with 
further information.  However the majority came from AJR retrospectively going 
through clinic lists to pre-screen potential participants.  Where patients met the 
inclusion/exclusion criteria on the basis of their clinic letter a covering letter was sent 
out by GC (in her capacity as the link clinician that patients had previously had contact 
with) enclosing an invitation from AJR, a Participant Information Sheet (PIS) and a 
(postage-paid) reply slip (Appendices A-C) – all approved by the Scotland REC A panel. 
 
All those who replied indicating they would be interested in participating in the study 
were telephoned by AJR.  Any missing information relevant to inclusion/exclusion 
criteria was checked in this phone call and then patients were offered an appointment 
for an initial screening visit. 
 
2.5.2 Informed consent 
All the participants had received the PIS at least 24 hours in advance of their 
attendance for a screening visit.  The programme of study visits was outlined and all 
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had the opportunity to ask questions prior to completing a written consent form (see 
Appendix D). 
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2.6 Study visits 
All study visits were conducted at the Department of Clinical Pharmacology, Ninewells 
Hospital, Dundee. 
 
Following written informed consent the screening visit continued, with an initial 
clinical assessment comprising of: 
 past medical history 
 allergies & drug history 
 family/social history 
 physical examination 
 height 
 weight 
 resting blood pressure 
 measurement of ABIs 
Following the above, the visit progressed to baseline exercise testing and phlebotomy.  
The tests involved are described in full in section 2.8.  The subsequent study visits 
involved combinations of these tests, as noted in Table 5 below.  Participants received 
oral and written confirmation of all study visits (see Appendix E for examples) 
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 Visit 1 (week 0) – screening visit 1 
o Participant consent – answer outstanding questions & complete consent form 
o Clinical assessment 
o Baseline ABI 
o Baseline ETT 
o Bloods for FBC/UE/LFT/uric acid/oxidised LDL 
o Record list of current medications 
 
 Visit 2 (week 0) – screening visit 2 
o Second baseline ETT – if stable (<25% variance) then can continue in study 
o Six minute walk test 
o FMD measurement 
o Supply of initial study medication to participant along with instructions 
o Walking Impairment Questionnaire 
o Quality of life (SF-36 questionnaire) 
o Record list of current medications 
 
 Visit 3 (week 6) – progress visit 
o Assess medication compliance 
o Check for AEs 
o Bloods for FBC/UE/LFT/oxidised LDL 
o Record list of current medications 
o Supply of full dose study medication (first half) 
 
 Visit 4 (week 12) – progress visit 
o ETT 
o Six minute walk test 
o Assess medication compliance 
o Check for AEs 
o Walking Impairment Questionnaire 
o Quality of life (SF-36 questionnaire) 
o Record list of current medications 
o Supply of full dose study medication (second half) 
 
 Visit 5 (week 18) – progress visit 
o FMD measurement 
o Assess medication compliance 
o Check for AEs 
o Bloods for FBC/UE/LFT 
o Record list of current medications 
 
 Visit 6 (week 24) – final visit 
o FMD measurement 
o ETT 
o Six minute walk test 
o ABI measurement 
o Assess medication compliance 
o Check for AEs 
o Bloods for FBC/UE/LFT/uric acid/oxidised LDL 
o Walking Impairment Questionnaire 
o Quality of life (SF-36 questionnaire) 
o Record list of current medications 
Table 5 – Study visit schedule  
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2.7 Randomisation & medication dosing 
All patients providing consent to enter the study were issued with a sequential 
screening number.  Those who remained eligible for inclusion in the study following 
their screening visits were issued with a sequential randomisation number and issued 
with the IMP matching that number. 
 
Randomisation had been carried out by Tayside Pharmaceuticals (Ninewells Hospital, 
Dundee) as supplier of the IMP, prior to commencement of study visits.  This was 
achieved through a computer generated randomisation system using five blocks of ten 
to ensure equal numbers between active and placebo groups.  The randomisation key 
was held in sealed envelopes by both Tayside Pharmaceuticals, Ninewells Pharmacy (in 
case of any need for emergency unblinding) and for safe-keeping in a locked fireproof 
cabinet by the Asthma & Allergy Research Group, Ninewells. 
 
Participants were randomised to receive either allopurinol or placebo for the six 
months of participation.  The initial dose was 100mg once daily of allopurinol (or 
placebo) for two weeks, rising to 300mg once daily allopurinol (or placebo) for four 
weeks, then continuing at 300mg twice daily of allopurinol (or placebo) for the 
remainder of the study.  Patients were provided with both verbal and written 
instructions regarding medication – the latter included a contact telephone number for 
AJR in case of any issues around tolerability (see Appendix F). 
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At time of randomisation and issuance of the initial medication supply a letter was sent 
to the participant’s GP (see Appendix G) and a copy filed in their medical notes (along 
with a copy of their signed consent form). 
 
Subsequent to completion of the trial all participants were formally thanked by letter.  
Following unblinding both participants and their GPs were informed of which group 
they had been in.  A summary of the trial results was sent to all participants after 
analysis had been completed.  Examples of these letters are shown in Appendix K.  
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2.8 Outcome measurements 
2.8.1 Primary and secondary endpoints 
The primary endpoint was the change in distance walked on an exercise tolerance test 
from baseline over a six month period.  This comprised of both the claudication onset 
distance (COD – when the participant first noticed claudication pain) and the peak 
walking distance (PWD – when they could walk no further and had to terminate the 
treadmill test). 
 
The overall secondary objectives were to (a) see if allopurinol improved the quality of 
life in patients with PAD and (b) to investigate the antioxidant effects of allopurinol in 
patients with PAD.  To that end there were a number of secondary endpoints: 
 Six minute walk test (6MWT) 
 Walking Impairment Questionnaire (WIQ) 
 Quality of Life (SF-36) questionnaire 
 Measurement of FMD to assess endothelial dysfunction 
 Measurement of oxidised LDL as a plasma marker of oxidative stress 
 
2.8.2 Exercise tolerance test 
These were conducted using the Gardner protocol, as is common in PAD studies 
testing efficacy of new treatments.23, 201  The machine used was a GE Marquette Series 
2000 Treadmill Stress Testing System (GE Healthcare Clinical Systems (UK) Ltd, 
Hatfield, UK).  The tests were conducted in accordance with the University of Dundee 
SOP for ETTs and were supervised by AJR (PI and Advanced Life Support instructor) and 
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a second member of staff.  Full resuscitation equipment (including external 
defibrillator) was available in the ETT room.  Although the main outcome measure for 
this study was claudication distance, the ECG electrodes were connected as usual to 
provide cardiac rhythm monitoring and the ability to assess ST segments should a 
participant complain of chest discomfort. 
 
Exercise testing became popular in the 1960s after Bruce and colleagues202 developed 
graded exercise protocols for patients with cardiac disease.  In PAD it was more 
popular to use a ‘constant load’ test at a defined grade (usually 1.5mph at 7.5% incline) 
until Gardner and colleagues in the early 1990s explored the use of a progressive 
exercise protocol.201  They showed intra-class correlation coefficients of COD and PWD 
during tests were R = 0.53 and R = 0.55, respectively for a single-stage/constant load 
treadmill test. By comparison, the respective R values utilising the progressive protocol 
were R = 0.89 and R = 0.93.  There is a great heterogeneity in the functional capability 
of patients with PAD, thus a progressive test allows for patients with a wide range of 
capabilities to be assessed.  A single-stage protocol is too fast for many patients, but 
for others is insufficiently taxing.  The 2% increase every two minutes with the Gardner 
protocol (at a constant speed of 2mph) ensures that most patients with PAD will 
become symptomatic during testing, whilst not proving too challenging in the early 
stages for those with more marked symptoms. 
 
There is some evidence that sequential testing of untreated patients with the graded 
treadmill test is not associated with a temporal improvement in the initial or absolute 
claudication distances or times.20, 23  This is potentially of benefit in clinical trials as 
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fewer participants are therefore required to elucidate any small but clinically 
important changes, however there is not unanimous agreement on this evidence, as 
will be covered further in the discussion section. 
 
ABIs play an important role in the initial diagnosis of PAD52, 73 and there is evidence 
that they have some role in follow-up – particularly in evaluating response to 
procedural intervention or restenosis.203  However there is also evidence that non-
procedural treatments may improve treadmill performance and functional status 
without a significant change in ABI.204  Change in ABI was therefore not considered to 
be a key outcome measure.  For the sake of completeness it is however included in 
section 3.9. 
 
2.8.3 Six minute walk test 
This was carried out as per American Thoracic Society guidelines, in a quiet corridor on 
a 30m track marked at 1m intervals.205  Participants were given standard instructions 
asking them to walk from one end to the other of the track as many times as possible 
in six minutes, stopping to rest if required and then continuing when they felt able.  
Standard encouragement was given every minute.  The total distance completed (to 
the nearest metre) was noted in the CRF.  The test was carried out at baseline and 
repeated on visits four and six. 
 
The 6MWT was originally developed in the 1980s as a useful alternative to the already 
established longer 12-minute walking test.206  It has most commonly been used in 
patients with COPD – hence the guidelines from the American Thoracic Society.  
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However it has also been studied in PAD, where it was found to yield highly reliable 
measurements, both by way of high reliability coefficient, low coefficient of variation 
and in correlation with claudication distances on graded treadmill testing.207 
 
2.8.4 Walking Impairment Questionnaire 
This questionnaire is widely used in the evaluation of PAD patient symptoms.  It was 
first developed by Regensteiner et al in 1990 and continues in widespread use today.20, 
208, 209  As well as being a short and straightforward questionnaire for patients to 
answer, it provides good correlation with patient performance on the treadmill, 
especially when stratifying them into high and low performers.210-212  It has also been 
demonstrated that in patients with PAD, lower WIQ stair-climbing scores are 
associated with higher all-cause and cardiovascular mortality, independent of their ABI 
or other covariates.213 
 
The questionnaire is designed to assess the day-to-day impact of intermittent 
claudication on patients.  It evaluates the site of pain (calves vs buttocks) and the 
degree to which different activities trigger symptoms – considering distance, speed 
and climbing stairs.  Given the heterogeneity of symptoms between patients it is 
crucial that all these domains are covered adequately, something that tends to be 
neglected in less condition-specific questionnaires.  Each of the three domains has a 
number of questions to assess the degree of difficult the patient is experiencing.  
Answers to each question are scored on a graded scale from 0 to 4 (with 0 
representing an inability to carry out the task and 4 representing no difficulty) – these 
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scores are then multiplied by a pre-specified weighting to provide summary scores for 
each domain and an overall score. 
 
The questionnaire (see Appendix H) was issued to patients to complete at baseline, 
mid-point and end of study visits.  It was carried out on arrival in the department (after 
walking from the front door of the hospital) to ensure they were well-rested prior to 
any exercise testing.  It has been validated for self-administration, therefore 
participants completed it themselves, with the exception of any questions they wished 
to clarify.214 
 
2.8.5 Quality of life (SF-36) Questionnaire 
The SF-36 is a multi-purpose, short-form health survey consisting of 36 questions.  It is 
a generic measure, rather than being targeted to any specific condition or age group.  
When scored it provides summary measures for functional health and well-being as 
well as a psychometrically-based physical and mental health summary.215  It has been 
widely utilised in thousands of studies previously, allowing for comparisons between 
conditions.  It was revised to v2 in 1996 to improve the instructions and layout to make 
it easier for patients to self-administer and to provide a subtler scale of responses 
rather than dichotomous replies.216  There is some previous discussion of using this 
questionnaire in patients with PAD and evidence that in addition to providing 
information on general health it is capable of detecting changes following intervention, 
especially in the physical functioning domain.217-219 
 
96 
 
The questionnaire (see Appendix I) was issued to patients to complete at baseline, 
mid-point and end of study visits.  Patients completed it themselves, with the 
exception of any questions they wished to clarify. 
2.8.6 Flow-mediated dilatation 
Flow-mediated dilatation is a non-invasive technique used to evaluate endothelial 
function.  It involves measurement of both arterial blood flow and vessel diameter – in 
the case of our department the brachial artery is used for these measurements. 
 
Following baseline measurements, a blood pressure cuff is inflated to supra-systolic 
pressures (200mmHg).  Occlusion of the brachial artery causes the tissues distal to the 
occlusion to become ischaemic.  Hypoxia, hypercapnoea and consequent decreasing 
pH lead to dilation of the vascular bed within the ischaemic area.  Consequent loss of 
vascular peripheral resistance allows effective reperfusion as the occlusion is released.  
Blood then flows with high velocity into the tissues fed by the brachial artery on cuff 
deflation.  The induced high-flow state through the brachial artery is called reactive 
hyperaemia and causes friction on the endothelium of the arterial wall.  This “shear 
stress” friction has been proposed as the trigger for endothelial release of NO.220 
 
The measurements are repeated following the administration of glyceryl trinitrate 
(GTN) spray.  The GTN acts as an exogenous NO donor, allowing for examination of the 
endothelium-independent dilatation and thus demonstrating the maximum obtainable 
vasodilator response. 
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Corretti quotes 40-60 patients in a parallel-group design study as being sufficient to 
demonstrate significant improvement, therefore the sample size involved in this study 
was felt to be sufficient.173 
 
Subsequent analysis of the recordings is then undertaken after the patient visit is 
complete.  Blood flow was expressed as the velocity time integral (VTI) (the area under 
the blood velocity/time curve for a complete cardiac cycle).  This was determined at 
baseline (mean of at least two measurements during the first minute of each study) 
and following cuff deflation. Baseline vessel diameter (mm) was defined as the mean 
of all measurements during the first minute of each study.  Maximal dilatation after 
hyperaemia was expressed as a percentage change from the baseline diameter.221 
 
Figure 19 provides an illustration of the setup used (courtesy Corretti et al.). 173  The 
diagram shows both upper and lower cuffs in place.  In an actual study only one cuff is 
used, although either upper or lower placement is recognised as being valid.  Custom 
and practice in our department was to opt for lower cuff placement.  An adjustable jig 
was used to hold the probe in place and ensure stability of the ultrasound image 
throughout each FMD study. 
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Figure 19 – Schematic drawing of brachial artery ultrasound imaging 
 
FMD was performed at the baseline visit, at visit 5 (week 18) and at end-point (visit 
6/week 24) using a Sequoia 512 (Siemens, Camberley, England) ultrasound machine 
with a 8 MHz linear array probe.  The protocol used to carry out the measurements 
was the standard one used in the department, as displayed towards the end of the CRF 
in Appendix J.  This is based on the International Brachial Artery Reactivity Task Force 
guidelines.173  The FMD was analysed using Brachial Analyzer for Research, part of the 
MIA Vascular Research Tools software suite (v.5.6.12, Medical Imaging Applications 
LLC, Coralville, Iowa), again using our departmental SOP. The acquisition and analysis 
of the FMD images were performed by AJR, who was blinded to the allocated 
treatment. 
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2.8.7 Laboratory tests 
A total volume of ~30ml venous blood was obtained on the initial visit.  This was then 
split into sample tubes as follows: 5ml EDTA for Ox-LDL, 5ml serum for storage, 10ml 
plasma from the EDTA tube for storage, 5ml serum for biochemistry, 4ml EDTA for 
haematology.  The haematology and biochemistry tubes were labelled with the 
participant’s NHS details and hand-delivered to the NHS blood sciences laboratory on 
Level 7, Ninewells. 
 
The study EDTA tubes were immediately put on ice and then centrifuged (along with 
the serum tube) for 10 minutes at 3,000rpm at 4oC within 15 minutes of venepuncture.  
The EDTA plasma was extracted from the centrifuged samples and transferred into 
microtubes for analysis.  These were individually labelled and then immediately stored 
at a -70oC freezer until a later date (when assays were carried out in batches). 
Venepuncture on subsequent visits was as described previously in Table 5. 
 
Full blood count, urea & electrolytes/liver function tests/uric acid 
As described above, all samples were hand delivered shortly after venepuncture to the 
NHS blood sciences laboratory (Ninewells Hospital, Dundee) where automated analysis 
was carried out to NHS Tayside standards.  Results were received back the following 
day and after any uric acid results were removed from the sheets (via photocopying by 
LM with uric acid results covered up) they were recorded in the CRF by AJR.  Any safety 
concerns arising from the routine haematology and biochemistry results were acted on 
appropriately by way of repeat sampling and where necessary IMP dose reduction. 
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In subsequent analysis the MDRD equation222 was used to calculate eGFR based on 
creatinine in µmol/L: 
eGF         Serum  reatinine       Age       [              ]  
[               ]  
The normal reference ranges for the NHS Tayside laboratory are as noted in Table 6.  
Partway through the study (February 2012) there was a major change in analyser 
equipment in the laboratory, from Roche to Siemens.  This led to some minor 
adjustments in reference ranges and in the case of albumin, a change in methodology 
(also see comment in results, section 3.2). 
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Test Normal reference range 
Haemoglobin 13.0 – 18.0 g/dL (men), 12.0 – 16.0 g/dL (women) 
White Cell Count 4.0 – 11.0 x109/L 
Platelets 150 – 400 x109/L 
Sodium 135 – 147 mmol/L 
Potassium 
3.5 – 5.0 mmol/L (Roche) 
3.5 – 5.3 mmol/L (Siemens) 
Urea 
3.3 – 6.6 mmol/L (Roche) 
2.5 – 7.8 mmol/L (Siemens) 
Creatinine 62 – 106 µmol/L (men), 44 –80 µmol/L (women) 
Alanine Transaminase (ALT) 
13 – 43 U/L (Roche) 
5 – 55 U/L (Siemens) 
Alkaline Phosphatase (ALP) 
40 – 130 U/L (Roche) 
30 – 130 U/L (Siemens) 
Bilirubin 
0 – 17 µmol/L (Roche) 
0 – 21 µmol/L (Siemens) 
Albumin 
36 – 50 g/L (Roche) 
35 – 50 g/L (Siemens) 
Table 6 – Normal reference ranges for NHS haematology and biochemistry tests 
 
Oxidised LDL 
Blood samples were obtained as noted above.  Subsequent blinded analysis was 
carried out by the Vascular & Inflammatory Diseases Research Unit in Ninewells using 
Mercodia Oxidised-LDL ELISA.  The background and rationale to selecting this test is 
discussed in full in section 4.2.6. 
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2.9 Data entry and management 
Data from each study visit was recorded in the paper CRF designed by AJR prior to the 
start of recruitment (Appendix J).  Treadmill printouts, blood results and questionnaire 
responses were all filed in the CRF (with the blood results sheets being suitably 
anonymised – the other items were labelled only by study ID).  FMD data files were 
transferred by magneto-optical disk to the analysis computer for storage (and backup 
on an external drive) – following analysis the results were transcribed into the CRF. 
 
Around the time of commencement of the study the Tayside Clinical Trials Unit had 
decided that electronic storage of study results should be carried out using the 
OpenClinica system.  However as this study was one of the first ‘live’ projects to be put 
onto this system by the TCTU developers there were a number of delays in the system 
being available for use.  As a result, data entry onto the system only finally started in 
the last month of the study and was essentially done retrospectively rather than as the 
study progressed (as had been originally envisaged).  All CRF data was double-data 
entered – first by TCTU staff and then by AJR.  All data entry and FMD analysis took 
place prior to unblinding – the database was locked and verified by TCTU staff 
following final data entry and secure copies were retained by TCTU prior to results 
being emailed to investigators and the trial statistician in the form of SPSS files. 
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2.10 Statistical analysis 
Analysis was undertaken by AJR using IBM SPSS Statistics version 20 (IBM Corp, NY, 
USA), with feedback obtained from LW on the initial analyses to confirm the correct 
procedures were being followed.  Following conclusion of the final trial visit (whilst 
data entry was still taking place) the copies of the allocation of treatment code held by 
both the NHS Tayside Pharmacy and the Asthma & Allergy Research Group were 
forwarded by the respective departments direct to TCTU.  Only after completion of 
data entry, when TCTU had carried out database verification and lock and had 
distributed results to the trial statistician were the codes made available to AJR. 
 
Data were checked for normality using the Shapiro-Wilk test given the smaller sample 
sizes involved in this study.  Where the significance value of the Shapiro-Wilk test was 
below 0.05 the data was assumed to be non-normally distributed.  In these situations 
it was log-transformed to see if this led to a normal distribution, thus allowing 
parametric analysis to be carried out.  If it remained non-normally distributed then 
non-parametric analysis was used.  Pearson’s chi-squared was used for discrete 
variables.  An independent samples t-test was used for normally-distributed 
continuous variables and a Mann-Whitney U test for non-parametric data.  For 
repeated comparisons within the same subject a paired t-test was used for normally-
distributed data and a Wilcoxon Signed-Rank matched pairs test for non-parametric 
data.  The study statistician (LW) was in agreement with this protocol. 
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2.11 Adverse events 
All adverse events were reported in accordance with The Medicines for Human Use 
(Clinical Trials) Amendment Regulations 2006.  At each study visit participants were 
asked about any adverse events since their last study visit, including any 
hospitalisation, unscheduled GP visits or new disabilities.  The sponsor was notified if 
there was a serious adverse event (SAE) or serious adverse reaction (SAR) except if it 
was a known adverse drug reaction that was set out in the Summary of Product 
Characteristics for allopurinol. 
 
A record was kept of all changes to the patients routinely prescribed medications 
throughout the study, as well as any acute prescriptions issued by their General 
Practitioner. 
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3 Results 
3.1 Recruitment 
As noted in section 2.5.1, with the exception of one patient (who directly approached 
AJR after seeing the trial listed on the ClinicalTrials.gov website) all patients in the 
study were recruited following their attendance at the Intermittent Claudication Clinic 
at Ninewells Hospital, Dundee.  Clinic lists from October 2009 to July 2011 were 
obtained and from these potential participants were identified.  The clinic consists of a 
mix of patients with potential/known PAD and those with wound care issues; however 
the groups were clearly distinguished on the clinic lists allowing attention to be 
focused on those attending due to probable/known PAD – a total of 673 potential 
participants.  Clinic letters for those patients were then screened to assess for 
potential eligibility to participate in the study – 519 were excluded at this stage due to 
failure to meet inclusion/exclusion criteria.  The remaining 154 received written 
invitations as previously described in section 2.5.1. 
 
The response rate from patients was excellent, with 74% (114/154) replying to the 
invitation letter.  Those who had indicated a willingness to be contacted further (73) 
were telephoned by AJR.  Of these, 66 attended for an initial screening visit – 16 failed 
screening, for the reasons noted in Figure 20 below.  The remaining 50 were 
randomised into the study.  This high conversion rate from screening to randomisation 
(76% - 50/66) was greatly aided by the high quality and thoroughness of the clinic 
letters that GC had written, which enabled early exclusion of those participants not 
meeting study criteria. 
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Following full NHS R&D approval in February 2011, full IMP manufacture was 
authorised.  This was delivered in mid-March – participant recruitment was only able 
to start when a confirmed delivery date for this had been received, therefore the first 
screening visit did not take place until early April.  The first ten participants had been 
randomised by the end of June 2011.  Unfortunately recruitment had to be put on hold 
at the start of September 2011 as there had been no further IMP delivery from Tayside 
Pharmaceuticals (due to issues at their end in receiving the allopurinol bulk power 
from their supplier).  Recruitment restarted after a three-week delay and the final 
screening visit was in early January 2012 with the last follow-up visit in June 2012. 
 
Withdrawals during the study itself were low – 5 in total (10%) – these were evenly 
split between active and placebo groups and reasons for withdrawal are as noted in 
the CONSORT diagram in Figure 20 below. 
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Figure 20 – CONSORT diagram 
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3.2 Baseline characteristics 
Of the 50 patients randomised, 78% (39/50) were male.  Participants had a mean (SD) 
age of 68.4 (1.2) years.  The baseline demographics were as outlined in Table 7 below. 
 
 
Allopurinol 
(n = 25) 
Placebo 
(n = 25) 
p 
Mean age (years) 69.6 (9.1) 67.3 (7.5) 0.34 
Male sex 21 (84%) 18 (72%) 0.50 
Height (m) 1.69 (0.09) 1.66 (0.07) 0.28 
Weight (kg) 77.7 (16.6) 80.6 (16.6) 0.36 
BMI (kg/m2) 27.2 (5.1) 29.1 (5.2) 0.21 
Pulse (bpm) 76.5 (11.6) 75.4 (14.9) 0.62 
Pack years 31.7 (21.0) 49.7 (37.0) 0.04 
Systolic BP (mmHg) 153 (21) 156 (20) 0.65 
Diastolic BP (mmHg) 76 (11) 79 (10) 0.27 
ABI 0.61 (0.12) 0.60 (0.12) 0.65 
Average weekly alcohol 
intake (units/week) 
7.4 (10.0) 16.8 (18.8) 0.08 
Smoking status 
Current smoker 
Ex-/non-smoker * 
 
6 
19 
 
7 
18 
 
0.75 
Table 7 – Baseline characteristics of participants 
 
Data displayed as mean (SD).  Pearson’s chi-squared was used for discrete variables, 
independent samples t-test for normally-distributed continuous variables and Mann-
Whitney U test for non-parametric data. 
 
* There were only two non-smokers in the study, both in the allopurinol group – to run 
a valid chi-squared test these there were combined with the non-smoker group. 
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Allopurinol 
(n = 25) 
Placebo 
(n = 25) 
p p 
Concomitant medications 
Aspirin/Clopidogrel 
Beta-blocker 
Statin 
ACEi/ARB 
PPI/H2-antagonist 
Long-acting nitrate 
GTN spray 
Painkiller 
Calcium-channel blocker 
Diuretic 
Naftidrofuryl 
 
24 (96%) 
5 (20%) 
23 (92%) 
17 (68%) 
9 (36%) 
1 (4%) 
6 (24%) 
6 (24%) 
13 (52%) 
7 (28%) 
2 (8%) 
 
23 (92%) 
9 (36%) 
24 (96%) 
18 (72%) 
5 (20%) 
1 (4%) 
3 (12%) 
6 (24%) 
9 (36%) 
4 (16%) 
1 (4%) 
 
0.88 
0.29 
0.88 
0.87 
0.29 
1.00 
0.32 
1.00 
0.39 
0.37 
0.56 
0.94 * 
Past Medical History 
Ischaemic heart disease 
Hypercholesterolaemia 
Hypertension 
COPD 
Diabetes mellitus 
GORD 
Vascular surg/intervention 
Other 
 
13 (52%) 
6 (24%) 
14 (56%) 
2 (8%) 
2 (8%) 
5 (20%) 
3 (12%) 
17 (68%) 
 
10 (40%) 
6 (24%) 
14 (56%) 
4 (16%) 
2 (8%) 
3 (12%) 
3 (12%) 
19 (76%) 
 
0.53 
1.00 
1.00 
0.41 
1.00 
0.48 
1.00 
0.74 
0.98 * 
Table 8 – Concomitant medications and past medical history 
 
* Advice was taken from the study statistician (LW) with regard to calculated p-values 
for comparing both these distributions.  If done line-by-line (see previous column) then 
a significant number of cells in the chi-squared test have a count of <5 – it was 
therefore suggested that an overall analysis of distribution be made, as shown in this 
column. 
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Baseline blood results comparing allopurinol versus placebo groups are as outlined 
below in Table 9. 
 
 
 
Allopurinol 
(n = 25) 
Placebo 
(n = 25) 
p 
Sodium (mmol/l) 
Potassium (mmol/l) 
Urea (mmol/l) 
Creatinine (mmol/l) 
GFR (ml/min) 
Haemoglobin (g/dl) 
WCC (x109/l) 
Neutrophils (x109/l) 
Platelets (x109/l) 
ALT (U/l) 
Bilirubin (µmol/l) * 
Alk Phos (U/l) 
Albumin (g/l) 
Oxidised LDL (U/l) 
Uric acid (mmol/l) 
141.1 (2.7) 
4.3 (0.2) 
6.1 (1.9) 
92.8 (18.5) 
74.3 (17.1) 
14.7 (1.4) 
8.1 (2.2) 
4.7 (1.9) 
254.8 (57.0) 
23.5 (11.6) 
9.1 (3.5) 
74.2 (18.4) 
47.9 (2.7) 
53.0 (17.8) 
0.36 (0.09) 
140.5 (3.4) 
4.5 (0.3) 
5.8 (1.8) 
87.9 (21.6) 
78.2 (20.0) 
14.7 (1.1) 
8.0 (2.1) 
4.9 (1.6) 
242.2 (53.2) 
33.1 (21.3) 
9.0 (5.0) 
84.1 (35.9) 
47.2 (2.4) 
49.4 (15.3) 
0.34 (0.09) 
0.59 
0.05 
0.62 
0.30 
0.53 
0.90 
0.91 
0.70 
0.42 
0.08 
0.62 
0.50 
0.37 
0.62 
0.98 
Table 9 – Baseline blood results of participants 
 
Data displayed as mean (SD).  Pearson’s chi-squared was used for discrete variables, 
independent samples t-test for normally-distributed continuous variables and Mann-
Whitney U test for non-parametric data. 
 
* Values <5 have been assumed to be equal to 5 for the purposes of statistical analysis 
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Safety blood results comparing initial and final visit results split into allopurinol and 
placebo groups are as outlined below in Table 10. 
 
 
 
Allopurinol 
Visit 1 
(n = 25) 
Allopurinol 
Visit 6 
(n=23) 
p 
Placebo 
Visit 1 
(n = 25) 
Placebo 
Visit 6 
(n = 22) 
p 
Sodium (mmol/L) 
Potassium (mmol/L) 
Urea (mmol/L) 
Creatinine (mmol/L) 
GFR (ml/min) 
Haemoglobin (g/dL) 
WCC (x109/L) 
Neutrophils (x109/L) 
Platelets (x109/L) 
ALT (U/L) 
Bilirubin (µmol/L) * 
Alk Phos (U/L) 
Albumin (g/L) 
141.1 (2.7) 
4.3 (0.2) 
6.1 (1.9) 
92.8 (18.5) 
74.3 (17.1) 
14.7 (1.4) 
8.1 (2.2) 
4.7 (1.9) 
254.8 (57.0) 
23.5 (11.6) 
9.1 (3.5) 
74.2 (18.4) 
47.9 (2.7) 
141.0 (2.2) 
4.4 (0.2) 
6.3 (1.4) 
86.8 (19.5) 
81.3 (24.5) 
14.5 (1.3) 
8.6 (1.9) 
5.2 (1.7) 
277.4 (60.2) 
29.1 (14.6) 
9.4 (2.7) 
82.7 (21.7) 
44.3 (4.0) 
0.43 
0.68 
0.79 
0.29 
0.30 
0.92 
0.48 
0.18 
0.15 
0.15 
0.21 
0.11 
0.002 
140.5 (3.4) 
4.5 (0.3) 
5.8 (1.8) 
87.9 (21.6) 
78.2 (20.0) 
14.7 (1.1) 
8.0 (2.1) 
4.9 (1.6) 
242.2 (53.2) 
33.1 (21.3) 
9.0 (5.0) 
84.1 (35.9) 
47.2 (2.4) 
140.2 (3.5) 
4.5 (0.3) 
5.8 (1.8) 
83.9 (21.5) 
83.2 (22.0) 
14.9 (1.3) 
7.1 (1.4) 
4.2 (1.2) 
247.0 (62.7) 
29.8 (13.0) 
9.8 (4.9) 
88.2 (45.3) 
44.2 (3.9) 
0.48 
0.47 
0.97 
0.44 
0.50 
0.36 
0.14 
0.22 
0.84 
0.99 
0.55 
0.83 
0.005 
Table 10 – Safety blood results comparing initial and final visits 
 
Data displayed as mean (SD).  Pearson’s chi-squared was used for discrete variables, 
paired t-test for normally-distributed continuous variables and Wilcoxon Signed Rank 
test for non-parametric data. 
 
* Values <5 have been assumed to be equal to 5 for the purposes of statistical analysis 
 
With regards the albumin results it can be seen there was a statistically significant 
reduction in both groups between the start and end of the study.  This has been 
discussed with Dr Ellie Dow, Consultant in Biochemical Medicine in the NHS Tayside 
112 
 
laboratory used for the study and it was felt these reductions were most likely due to a 
change in methodology used in the laboratory. The original method (at the time of V1 
sampling) made use of bromocresol purple, but during the course of the study the 
laboratory switched to using bromocresol green, which is felt to be closer to gold 
standard and actually more accurate at the lower end. 
  
113 
 
3.3 Adherence to medication 
Uric acid levels were checked on both initial and final visits, giving a good idea of 
concordance with treatment.  As noted in Table 9 there was no significant difference in 
baseline uric acid levels between the two groups (p=0.98).  It can be seen in Figure 21 
below that there was a highly significant drop in uric acid for those on treatment, with 
an order of magnitude of 52.1% (p<0.001).  A small 10.0% drop was noted in the 
placebo group but this was not statistically significant (p=0.06).  Two participants had 
either no change or an increase in uric acid level between start and end of the study, 
suggesting at least a period of non-compliance.  All other participants in the active 
treatment arm had >13% reduction, with the majority a 40-60% reduction as indicated 
by the aforementioned mean. 
 
Baseline Visit 6
0.0
0.1
0.2
0.3
0.4
0.5 p=0.98 p=<0.001
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Figure 21 – Reduction in uric acid (vertical bars indicate 95% CI) 
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3.4 Adverse events 
A total of 16 adverse events were reported in total, eight in each group.  Table 11 
summarises the reasons for these events.  One patient had three adverse events and 
one had two, thus a total of 13 patients reported adverse events.  Nine of the events 
were felt to be unrelated to the study drug.  Of the other seven events the IMP was 
stopped in three cases and the dose reduced in a further three (UEs were rechecked in 
the remaining case). 
 
One participant experienced a serious adverse event during the study, suffering a 
community acquired pneumonia that required hospital admission.  This ended up 
being a prolonged admission and following discharge home they elected to withdraw 
from the study. 
 
 Allopurinol Placebo 
Chest discomfort 1  
Chest infection  2 
Diarrhoea  1 
Dizziness 1  
Hospitalisation (SAE) 1  
Hyponatraemia  1 
Joint pain 2 3 
Minor deterioration in UEs 1  
Raised ALT  1 
SOB 1  
Soft tissue infection 1  
Table 11 – Adverse events 
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3.5 Treadmill 
The output from OpenClinica provided a time in seconds for each treadmill test for 
both onset of claudication and peak walking time.  Given the constant 2mph speed of 
the treadmill throughout the test it was possible to convert this into a more clinically 
meaningful distance in metres (time in seconds x 0.89408ms-1). 
 
The change in claudication onset and peak walking distance was then analysed, 
comparing those on allopurinol with those on placebo.  The natural logs of the 
distances involved were used to provide normal distribution for the data prior to either 
independent (between treatment group) or paired (within treatment group) t-tests 
being carried out. 
 
The data was then sub-divided by a variety of factors: 
 Factor: above/below median baseline claudication onset (section 3.5.2) 
 Factor: above/below median baseline peak walking distance (section 3.5.3) 
 Factor: above/below median baseline uric acid (section 3.5.4) 
 Factor: above/below median baseline systolic BP (section 3.5.5) 
 Factor: above/below median baseline ABI (section 3.5.6) 
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3.5.1 Without any sub-division by factor 
Table 12 below shows the claudication onset distances for each treatment arm at 
different stages of the study.  The baseline figure is the mean of Visit 1 and Visit 2 as 
was pre-specified in the study protocol. 
 
Time point 
Allopurinol 
(95% CI) 
Placebo 
(95% CI) 
p 
Baseline 
(metres) 
137.1 
(82.0 to 192.2) 
151.7 
(105.4 to 198.0) 
0.31 
Visit 4 
(metres) 
161.7 
(109.0 to 214.3) 
155.0 
(110.2 to 200.0) 
0.95 
Visit 6 
(metres) 
180.0 
(111.5 to 248.6) 
177.1 
(133.1 to 221.2) 
0.48 
Table 12 – COD in metres at different study stages 
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Figure 22 – COD in metres at different study stages 
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The change in claudication onset distance from baseline is shown in Table 13 and 
Figure 23. 
 
Allopurinol 
(95% CI) 
Placebo 
(95% CI) 
P 
Mean change from 
Baseline to Visit 4 
(metres) 
19.4 
(-11.1 to 49.8) 
25.0 
(8.3 to 41.6) 
0.82 
Mean change from 
Baseline to Visit 6 
(metres) 
37.7 
(3.7 to 71.8) 
47.1 
(19.9 to 74.3) 
0.35 
Table 13 – Absolute change in COD from baseline 
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Figure 23 – Mean absolute change in COD (vertical bars indicate 95% CI) 
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Given the variability in baseline walking distances noted in Table 12, the mean relative 
change was calculated and is shown in Table 14 and Figure 24 below. 
 
Allopurinol 
(95% CI) 
Placebo 
(95% CI) 
P 
Relative increase 
from Baseline to Visit 
4 
0.34 
(0.14 to 0.54) 
0.23 
(0.10 to 0.37) 
0.52 
Relative increase 
from Baseline to Visit 
6 
0.41 
(0.11 to 0.70) 
0.50 
(0.26 to 0.75) 
0.47 
Table 14 – Relative increase in COD from baseline 
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Figure 24 – Relative increase in COD (vertical bars indicate 95% CI) 
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The individual change for each participant is shown in Figure 25 and Figure 26 below. 
 
 
Figure 25 – Relative increase in COD (individual participants on allopurinol) 
 
Figure 26 – Relative increase in COD (individual participants on placebo)  
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Table 15 below shows the peak walking distances for each arm of the study at the 
different stages.  The baseline figure is the mean of Visit 1 and Visit 2 as outlined in the 
study protocol. 
 
Time point 
Allopurinol 
(95% CI) 
Placebo 
(95% CI) 
P 
Baseline 
(metres) 
315.5 
(206.0 to 425.0) 
362.6 
(266.4 to 458.8) 
0.24 
Visit 4 
(metres) 
320.1 
(209.0 to 431.2) 
341.5 
(256.9 to 426.1) 
0.42 
Visit 6 
(metres) 
347.4 
(224.8 to 470.0) 
358.4 
(253.9 to 462.9) 
0.61 
Table 15 – PWD in metres at different study stages 
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Figure 27 – PWD in metres at different study stages 
 
121 
 
The change in peak walking distance from baseline is shown in Table 16 and Figure 28. 
 
Allopurinol 
(95% CI) 
Placebo 
(95% CI) 
P 
Mean change from 
Baseline to Visit 4 
(metres) 
-10.1 
(-47.5 to 27.2) 
19.3 
(-19.4 to 58.1) 
0.28 
Mean change from 
Baseline to Visit 6 
(metres) 
17.1 
(-18.5 to 52.8) 
36.2 
(-4.3 to 76.8) 
0.34 
Table 16 – Absolute change in PWD from baseline 
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Figure 28 – Mean absolute change in PWD (vertical bars indicate 95% CI) 
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Given the variability in baseline walking distances noted in Table 12, the mean relative 
change was also calculated and is shown in Table 17 and Figure 29 below. 
 
 
Allopurinol 
(95% CI) 
Placebo 
(95% CI) 
P 
Relative increase 
from Baseline to Visit 
4 
0.01 
(-0.11 to 0.14) 
0.12 
(-0.04 to 0.27) 
0.35 
Relative increase 
from Baseline to Visit 
6 
0.14 
(-0.07 to 0.34) 
0.12 
(0.01 to 0.24) 
0.40 
Table 17 – Relative increase in PWD from baseline 
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Figure 29 – Mean relative increase in PWD (vertical bars indicate 95% CI) 
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The individual change for each participant is shown in Figure 30 and Figure 31. 
 
 
Figure 30 – Relative increase in PWD (individual participants on allopurinol) 
 
 
Figure 31 – Relative increase in PWD (individual participants on placebo) 
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To safeguard against the impact of any missing data, analysis of the primary outcome 
was also performed following multiple imputation.  As demonstrated in Table 18 and 
Table 19, all P values remained non-significant following this analysis. 
 
Time point 
Allopurinol 
(95% CI) 
Placebo 
(95% CI) 
p 
(imputed data) 
Baseline 
(metres) 
137.1 
(82.0 to 192.2) 
151.7 
(105.4 to 198.0) 
0.31 
Visit 4 
(metres) 
155.7 
(134.8 to 176.6) 
174.4 
(154.3 to 194.5) 
0.39 
Visit 6 
(metres) 
172.5 
(145.4 to 199.7) 
195.6 
(175.3 to 215.9) 
0.20 
Table 18 – COD in metres at different study stages following multiple imputation 
 
Time point 
Allopurinol 
(95% CI) 
Placebo 
(95% CI) 
p 
(imputed data) 
Baseline 
(metres) 
315.5 
(206.0 to 425.0) 
362.6 
(266.4 to 458.8) 
0.24 
Visit 4 
(metres) 
307.7 
(263.6 to 351.7) 
373.7 
(336.2 to 411.2) 
0.13 
Visit 6 
(metres) 
334.3 
(285.7 to 383.0) 
396.1 
(351.5 to 440.8) 
0.12 
Table 19 – PWD in metres at different study stages following multiple imputation  
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3.5.2 Factor: above/below median baseline claudication onset 
The median claudication onset distance at baseline was 98.4m.  The participants were 
split into two groups – those below and those above this median level.  The relative 
increases in both claudication onset distance and peak walking distance were then 
calculated. 
 
Allopurinol 
(95% CI) 
Placebo 
(95% CI) 
p 
Relative increase in 
COD from Baseline to 
Visit 4 
Below median 
baseline COD 
0.55 
(0.25 to 0.85) 
0.29 
(0.07 to 0.51) 
0.45 
Above median 
baseline COD 
0.11 
(-0.13 to 0.36) 
0.18 
(-0.02 to 0.38) 
0.70 
Relative increase in 
COD from Baseline to 
Visit 6 
Below median 
baseline COD 
0.53 
(0.13 to 0.93) 
0.74 
(0.38 to 1.09) 
0.35 
Above median 
baseline COD 
0.27 
(-0.22 to 0.76) 
0.27 
(-0.07 to 0.60) 
0.75 
Table 20 – Relative increase in COD split by low/high baseline COD 
 
Baseline Visit 4 Visit 6
-50
0
50
100
150
Allopurinol - low base COD
Allopurinol - high base COD
Placebo - low base COD
Placebo - high base COD
R
e
la
ti
v
e
 i
n
c
re
a
s
e
 (
%
)
 
Figure 32 – Relative increase in COD split by low/high baseline COD  
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Allopurinol 
(95% CI) 
Placebo 
(95% CI) 
p 
Relative increase in 
PWD from Baseline to 
Visit 4 
Below median 
baseline COD 
0.03 
(-0.20 to 0.26) 
0.29 
(0.07 to 0.51) 
0.45 
Above median 
baseline COD 
0.00 
(-0.14 to 0.14) 
0.18 
(-0.02 to 0.38) 
0.75 
Relative increase in 
PWD from Baseline to 
Visit 6 
Below median 
baseline COD 
0.24 
(-0.14 to 0.63) 
0.16 
(-0.02 to 0.34) 
0.74 
Above median 
baseline COD 
0.02 
(-0.12 to 0.17) 
0.09 
(-0.08 to 0.25) 
0.48 
Table 21 – Relative increase in PWD split by low/high baseline COD 
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Figure 33 – Relative increase in PWD split by low/high baseline COD 
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3.5.3 Factor: above/below median baseline peak walking distance 
The median peak walking distance at baseline was 278.1m.  The participants were split 
into two groups – those below and those above this median level.  The relative 
increases in both claudication onset distance and peak walking distance were then 
calculated. 
 
 
Allopurinol 
(95% CI) 
Placebo 
(95% CI) 
p 
Relative increase in 
COD from Baseline to 
Visit 4 
Below median 
baseline PWD 
0.49 
(0.14 to 0.85) 
0.20 
(0.00 to 0.40) 
0.41 
Above median 
baseline PWD 
0.20 
(-0.04 to 0.44) 
0.28 
(0.05 to 0.50) 
0.82 
Relative increase in 
COD from Baseline to 
Visit 6 
Below median 
baseline PWD 
0.37 
(-0.10 to 0.84) 
0.36 
(0.03 to 0.69) 
0.79 
Above median 
baseline PWD 
0.44 
(0.01 to 0.87) 
0.70 
(0.27 to 1.09) 
0.23 
Table 22 – Relative increase in COD split by low/high baseline PWD 
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Figure 34 – Relative increase in COD split by low/high baseline PWD 
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Allopurinol 
(95% CI) 
Placebo 
(95% CI) 
p 
Relative increase in 
PWD from Baseline to 
Visit 4 
Below median 
baseline PWD 
0.08 
(-0.17 to 0.32) 
0.15 
(-0.14 to 0.44) 
0.88 
Above median 
baseline PWD 
-0.04 
(-0.18 to 0.10) 
0.07 
(-0.08 to 0.23) 
0.28 
Relative increase in 
PWD from Baseline to 
Visit 6 
Below median 
baseline PWD 
0.24 
(-0.19 to 0.67) 
0.10 
(-0.08 to 0.28) 
0.93 
Above median 
baseline PWD 
0.04 
(-0.09 to 0.17) 
0.16 
(0.00 to 0.32) 
0.23 
Table 23 – Relative increase in PWD split by low/high baseline PWD 
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Figure 35 – Relative increase in PWD split by low/high baseline PWD 
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3.5.4 Factor: above/below median baseline uric acid 
The median uric acid at baseline was 0.36mmol/l.  The participants were split into two 
groups – those below and those above this median level.  The relative increases in 
both claudication onset distance and peak walking distance were then calculated. 
 
 
Allopurinol 
(95% CI) 
Placebo 
(95% CI) 
p 
Relative increase in 
COD from Baseline to 
Visit 4 
Below median 
baseline urate 
0.37 
(0.12 to 0.61) 
0.17 
(-0.05 to 0.38) 
0.32 
Above median 
baseline urate 
0.30 
(-0.10 to 0.71) 
0.28 
(0.08 to 0.48) 
0.78 
Relative increase in 
COD from Baseline to 
Visit 6 
Below median 
baseline urate 
0.33 
(0.06 to 0.60) 
0.27 
(-0.09 to 0.62) 
0.85 
Above median 
baseline urate 
0.51 
(-0.15 to 1.16) 
0.67 
(0.32 to 1.01) 
0.31 
Table 24 – Relative increase in COD split by low/high baseline urate 
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Figure 36 – Relative increase in COD split by low/high baseline urate 
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Allopurinol 
(95% CI) 
Placebo 
(95% CI) 
P 
Relative increase in 
PWD from Baseline to 
Visit 4 
Below median 
baseline urate 
-0.13 
(-0.25 to -0.01) 
0.11 
(-0.20 to 0.42) 
0.11 
Above median 
baseline urate 
0.21 
(0.00 to 0.42) 
0.12 
(-0.08 to 0.33) 
0.69 
Relative increase in 
PWD from Baseline to 
Visit 6 
Below median 
baseline urate 
-0.02 
(-0.14 to 0.09) 
0.08 
(-0.16 to 0.33) 
0.39 
Above median 
baseline urate 
0.35 
(-0.11 to 0.80) 
0.15 
(-0.02 to 0.28) 
0.88 
Table 25 – Relative increase in PWD split by low/high baseline urate 
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Figure 37 – Relative increase in PWD split by low/high baseline urate 
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When considering Figure 37 above, it can be seen that the lines for PWD in the 
allopurinol group appear to be slightly diverging, albeit with overlapping confidence 
intervals.  To check for any difference between the low and high baseline urate sub-
populations the baseline characteristics for these two groups were compared – no 
significant difference in any factor was found. 
 
Also considered for those in the active treatment group was whether the percentage 
reduction in uric acid (i.e. the relative response to allopurinol) made any difference to 
the change in either claudication onset or peak walking distance.  The median 
reduction in uric acid for those on allopurinol was 57.0% and this was used to split the 
active group in two.  As can been seen in Figure 38 and Figure 39 below there was no 
significant difference between those that had a reduction in uric acid either above or 
below this median level. 
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Figure 38 – Relative increase in COD for low vs high reduction in uric acid 
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Figure 39 – Relative increase in PWD for low vs high reduction in uric acid 
3.5.5 Factor: above/below median baseline systolic BP 
The median systolic BP at baseline was 154.5mmHg.  The participants were split into 
two groups – those below and those above this median level.  The relative increases in 
both claudication onset distance and peak walking distance were then calculated. 
 
 
Allopurinol 
(95% CI) 
Placebo 
(95% CI) 
p 
Relative increase in 
COD from Baseline to 
Visit 4 
Below median 
baseline systolic 
BP 
0.32 
(0.02 to 0.62) 
0.28 
(0.09 to 0.46) 
0.95 
Above median 
baseline systolic 
BP 
0.36 
(0.04 to 0.68) 
0.19 
(-0.04 to 0.42) 
0.70 
Relative increase in 
COD from Baseline to 
Visit 6 
Below median 
baseline systolic 
BP 
0.36 
(-0.10 to 0.82) 
0.75 
(0.39 to 1.12) 
0.05 
Above median 
baseline systolic 
BP 
0.45 
(0.01 to 0.89) 
0.25 
(-0.05 to 0.56) 
0.61 
Table 26 – Relative increase in COD split by low/high baseline systolic BP 
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Figure 40 – Relative increase in COD split by low/high baseline systolic BP 
 
Allopurinol 
(95% CI) 
Placebo 
(95% CI) 
p 
Relative increase in 
PWD from Baseline to 
Visit 4 
Below median 
baseline systolic 
BP 
-0.01 
(-0.12 to 0.10) 
0.13 
(-0.17 to 0.43) 
0.52 
Above median 
baseline systolic 
BP 
0.03 
(-0.21 to 0.28) 
0.10 
(-0.07 to 0.28) 
0.57 
Relative increase in 
PWD from Baseline to 
Visit 6 
Below median 
baseline systolic 
BP 
0.04 
(-0.08 to 0.16) 
0.15 
(-0.03 to 0.33) 
0.44 
Above median 
baseline systolic 
BP 
0.23 
(-0.17 to 0.62) 
0.10 
(-0.07 to 0.27) 
0.88 
Table 27 – Relative increase in PWD split by low/high baseline systolic BP 
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Figure 41 – Relative increase in PWD split by low/high baseline systolic BP 
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3.5.6 Factor: above/below median baseline ABI 
The median ABI at baseline was 0.60.  The participants were split into two groups – 
those below and those above this median level.  The relative increases in both 
claudication onset distance and peak walking distance were then calculated. 
 
 
Allopurinol 
(95% CI) 
Placebo 
(95% CI) 
p 
Relative increase in 
COD from Baseline to 
Visit 4 
Below median 
baseline ABI 
0.29 
(-0.02 to 0.60) 
0.17 
(-0.07 to 0.41) 
1.00 
Above median 
baseline ABI 
0.40 
(0.08 to 0.71) 
0.29 
(0.10 to 0.47) 
0.61 
Relative increase in 
COD from Baseline to 
Visit 6 
Below median 
baseline ABI 
0.51 
(-0.03 to 1.04) 
0.29 
(0.02 to 0.55) 
0.87 
Above median 
baseline ABI 
0.30 
(0.00 to 0.60) 
0.69 
(0.29 to 1.08) 
0.13 
Table 28 – Relative increase in COD split by low/high baseline ABI 
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Figure 42 – Relative increase in COD split by low/high baseline ABI 
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Allopurinol 
(95% CI) 
Placebo 
(95% CI) 
p 
Relative increase in 
PWD from Baseline to 
Visit 4 
Below median 
baseline ABI 
0.05 
(-0.12 to 0.22) 
0.16 
(-0.16 to 0.48) 
0.87 
Above median 
baseline ABI 
-0.02 
(-0.25 to 0.20) 
0.08 
(-0.09 to 0.25) 
0.26 
Relative increase in 
PWD from Baseline to 
Visit 6 
Below median 
baseline ABI 
0.15 
(-0.14 to 0.43) 
0.14 
(-0.07 to 0.34) 
0.77 
Above median 
baseline ABI 
0.13 
(-0.21 to 0.47) 
0.11 
(-0.04 to 0.27) 
0.35 
Table 29 – Relative increase in PWD split by low/high baseline ABI 
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Figure 43 – Relative increase in PWD split by low/high baseline ABI 
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3.6 Six Minute Walk Test 
Data from OpenClinica provided a total walking distance in metres for each 6MWT.  
The absolute and relative change in six-minute walk distance (6MWD) was then 
calculated, comparing those on allopurinol with those on placebo. 
 
The data was initially analysed without any subdivision (section 3.6.1).  It was then sub-
divided by two different factors: 
 Factor: above/below median baseline six-minute walk distance (section 3.6.2) 
 Factor: above/below median baseline uric acid (section 3.6.3) 
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3.6.1 Without any sub-division by factor 
Table 30 and Figure 44 below show the six minute walk test distance reached for each 
treatment arm at different stages of the study. 
 
Time point 
Allopurinol 
(95% CI) 
Placebo 
(95% CI) 
p 
Baseline 
(metres) 
401.2 
(371.7 to 430.7) 
389.1 
(369.2 to 409.1) 
0.72 
Visit 4 
(metres) 
396.3 
(366.1 to 426.6) 
395.6 
(376.3 to 414.8) 
0.97 
Visit 6 
(metres) 
398.2 
(374.4 to 422.1) 
399.9 
(375.8 to 424.0) 
0.92 
Table 30 – 6MWD in metres at different study stages 
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Figure 44 – 6MWD in metres at different study stages 
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The change in six minute walk test distance from baseline is shown in Table 31 and 
Figure 45. 
 
 
 
Allopurinol 
(95% CI) 
Placebo 
(95% CI) 
p 
Mean change from 
Baseline to Visit 4 
(metres) 
4.4 
(-10.5 to 19.4) 
8.7 
(-2.4 to 19.8) 
0.73 
Mean change from 
Baseline to Visit 6 
(metres) 
6.4 
(-3.9 to 16.6) 
13.1 
(1.0 to 25.1) 
0.63 
Table 31 – Absolute change in 6MWD from baseline 
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Figure 45 – Mean absolute change in 6MWD (vertical bars indicate 95% CI) 
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Given the range of baseline walking distances noted in Table 30, the mean relative 
change was calculated and is shown in Table 32 and Figure 46 below. 
 
 
Allopurinol 
(95% CI) 
Placebo 
(95% CI) 
p 
Relative increase 
from Baseline to Visit 
4 
0.01 
(-0.03 to 0.05) 
0.03 
(0.00 to 0.06) 
0.70 
Relative increase 
from Baseline to Visit 
6 
0.02 
(-0.01 to 0.05) 
0.03 
(0.00 to 0.07) 
0.56 
Table 32 – Relative increase in 6MWD from baseline 
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Figure 46 – Relative increase in 6MWD (vertical bars indicate 95% CI) 
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The individual change for each participant is shown in Figure 47 and Figure 48 below. 
 
 
Figure 47 – Relative increase in 6MWD (individual participants on allopurinol) 
 
Figure 48 – Relative increase in 6MWD (individual participants on placebo) 
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3.6.2 Factor: above/below median baseline six-minute walk distance 
The median baseline six minute walk distance was 393m.  The participants were split 
into two groups – those below and those above this median level.  The relative 
increases in walking distance for each group were then calculated. 
 
 
Allopurinol 
(95% CI) 
Placebo 
(95% CI) 
p 
Relative increase in 
6MWD from Baseline 
to Visit 4 
Below median 
baseline 6MWD 
-0.01 
(-0.09 to 0.07) 
0.06 
(0.02 to 0.11) 
0.12 
Above median 
baseline 6MWD 
0.03 
(0.00 to 0.06) 
0.01 
(-0.03 to 0.04) 
0.73 
Relative increase in 
6MWD from Baseline 
to Visit 6 
Below median 
baseline 6MWD 
0.01 
(-0.03 to 0.06) 
0.01 
(-0.06 to 0.07) 
0.40 
Above median 
baseline 6MWD 
0.02 
(-0.01 to 0.06) 
0.05 
(0.01 to 0.09) 
0.43 
Table 33 – Relative increase in 6MWD split by low/high baseline 6MWD 
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Figure 49 – Relative increase in 6MWD split by low/high baseline 6MWD 
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3.6.3 Factor: above/below median baseline uric acid 
The median uric acid at baseline was 0.36mmol/l.  The participants were split into two 
groups – those below and those above this median level.  The relative increases in 
walking distance for each group were then calculated. 
 
 
Allopurinol 
(95% CI) 
Placebo 
(95% CI) 
p 
Relative increase in 
6MWD from Baseline 
to Visit 4 
Below median 
baseline urate 
0.00 
(-0.07 to 0.08) 
0.03 
(-0.01 to 0.07) 
0.85 
Above median 
baseline urate 
0.02 
(-0.02 to 0.06) 
0.02 
(-0.02 to 0.07) 
0.74 
Relative increase in 
6MWD from Baseline 
to Visit 6 
Below median 
baseline urate 
0.02 
(-0.01 to 0.06) 
0.05 
(0.00 to 0.09) 
0.36 
Above median 
baseline urate 
0.01 
(-0.03 to 0.06) 
0.03 
(-0.02 to 0.07) 
1.00 
Table 34 – Relative increase in 6MWD split by low/high baseline urate 
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Figure 50 – Relative increase in 6MWD split by low/high baseline urate 
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Also considered for the active treatment group was whether the percentage reduction 
in uric acid (i.e. the relative response to allopurinol) made any difference to the change 
in six minute walk distance.  The median reduction in uric acid for those on allopurinol 
was 57.0% and this was used to split the active group in two.  As can been seen in 
Figure 51 below there was no significant difference between those that had a 
reduction in uric acid either above or below this median level. 
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Figure 51 – Relative increase in 6MWD for low vs high reduction in uric acid 
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3.7 Blood pressure 
As outlined in Table 7, there was no significant difference in blood pressure readings at 
baseline in the two treatment groups.  Blood pressure had not been identified as a key 
outcome measure in the study protocol therefore it was not re-measured in the same 
way as many other characteristics at the end of the study.  A blood pressure was 
however checked prior to six-minute walk testing at the start and end of the study.  It 
should be noted though that for the vast majority of patients this followed FMD testing 
and therefore was a measurement taken after the use of GTN in the latter part of that 
test. 
 
Within that limitation, comparison of these post-GTN blood pressures is shown in 
Table 35 (comparison between allopurinol and placebo at start and end of study), 
Table 36 (comparison between start and end of study by treatment group) and 
illustrated in Figure 52 below. 
 
 
Allopurinol 
Visit 2 
(95% CI) 
Placebo 
Visit 2 
(95% CI) 
p 
Allopurinol 
Visit 6 
(95% CI) 
Placebo 
Visit 6 
(95% CI) 
p 
Systolic BP 
(mmHg) 
118 
(110 to 
126) 
121 
(113 to 
130) 
0.54 
123 
(116 to 
131) 
122 
(116 to 
127) 
0.71 
Diastolic BP 
(mmHg) 
67 
(63 to 72) 
70 
(66 to 74) 
0.30 
68 
(64 to 72) 
71 
(68 to 75) 
0.26 
Table 35 – Post-GTN pre-6MWT blood pressures (allopurinol vs placebo) 
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Allopurinol 
Visit 2 
(95% CI) 
Allopurinol 
Visit 6 
(95% CI) 
p 
Placebo 
Visit 2 
(95% CI) 
Placebo 
Visit 6 
(95% CI) 
p 
Systolic BP 
(mmHg) 
118 
(110 to 
126) 
123 
(116 to 
131) 
0.30 
121 
(113 to 
130) 
122 
(116 to 
127) 
0.93 
Diastolic BP 
(mmHg) 
67 
(63 to 72) 
68 
(64 to 72) 
0.81 
70 
(66 to 74) 
71 
(68 to 75) 
0.72 
Table 36 – Post-GTN pre-6MWT blood pressures (start vs end of study) 
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Figure 52 – Post-GTN pre-6MWT blood pressures 
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3.8 FMD 
Analysis was carried out as described in section 2.8.6, for both post-cuff deflation 
(Table 37 and Figure 53) and post-GTN (Table 38 and Figure 54) flow-mediated 
dilatation. 
Time point 
Allopurinol 
(95% CI) 
Placebo 
(95% CI) 
p 
Baseline vessel size 
(mm) 
4.66 
(4.34 to 4.98) 
4.24 
(3.75 to 4.73) 
0.14 
Absolute change post-cuff 
at baseline 
(mm) 
0.38 
(0.25 to 0.51) 
0.34 
(0.19 to 0.50) 
0.65 
Relative change post-cuff 
at baseline 
(%) 
8.33 
(5.87 to 10.79) 
9.61 
(4.92 to 14.30) 
0.84 
Absolute change post-cuff 
at Visit 5 
(mm) 
0.24 
(0.16 to 0.31) 
0.24 
(0.13 to 0.34) 
0.66 
Relative change post-cuff 
at Visit 5 
(%) 
4.85 
(3.46 to 6.24) 
5.61 
(3.54 to 7.69) 
0.32 
Relative change compared 
to baseline post-cuff at 
Visit 5 
(%) 
-0.29 
(-0.53 to -0.06) 
-0.15 
(-0.59 to 0.28) 
0.42 
Absolute change post-cuff 
at Visit 6 
(mm) 
0.41 
(0.30 to 0.52) 
0.25 
(0.14 to 0.36) 
0.06 
Relative change post-cuff 
at Visit 6 
(%) 
8.92 
(6.43 to 11.40) 
6.55 
(3.49 to 9.61) 
0.27 
Relative change compared 
to baseline post-cuff at 
Visit 6 
(%) 
0.41 
(-0.30 to 1.11) 
-0.28 
(-0.64 to 0.09) 
0.32 
Table 37 – Baseline vessel diameter and percentage change throughout study (cuff) 
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Figure 53 – Relative change in vessel diameter throughout study (cuff) 
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Time point 
Allopurinol 
(95% CI) 
Placebo 
(95% CI) 
p 
Baseline vessel size 
(mm) 
4.80 
(4.49 to 5.11) 
4.45 
(3.96 to 4.94) 
0.13 
Absolute change post-GTN 
at baseline 
(mm) 
0.46 
(0.39 to 0.53) 
0.45 
(0.36 to 0.55) 
0.35 
Relative change post-GTN 
at baseline 
(%) 
9.94 
(7.92 to 11.96) 
11.04 
(7.48 to 14.60) 
0.96 
Absolute change post-GTN 
at Visit 5 
(mm) 
0.33 
(0.26 to 0.40) 
0.45 
(0.35 to 0.55) 
0.52 
Relative change post-GTN 
at Visit 5 
(%) 
6.57 
(5.10 to 8.05) 
10.50 
(7.73 to 13.27) 
0.01 
Relative change compared 
to baseline post-GTN at 
Visit 5 
(%) 
-0.25 
(-0.47 to -0.02) 
0.02 
(-0.39 to 0.43) 
0.11 
Absolute change post-GTN 
at Visit 6 
(mm) 
0.41 
(0.32 to 0.50) 
0.43 
(0.28 to 0.57) 
0.39 
Relative change post-GTN 
at Visit 6 
(%) 
8.38 
(6.47 to 10.29) 
9.59 
(6.21 to 12.97) 
0.62 
Relative change compared 
to baseline post-GTN at 
Visit 6 
(%) 
-0.04 
(-0.33 to 0.25) 
0.01 
(-0.61 to 0.62) 
0.80 
Table 38 – Baseline vessel diameter and percentage change throughout study (GTN) 
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Figure 54 – Relative change in vessel diameter throughout study (GTN) 
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The other parameter assessed during the cuff inflation/deflation was the change in 
brachial artery blood flow – this was through assessment of the velocity-time integral 
(VTI) of the flow measured via pulse-wave doppler. 
 
Comparison of these VTIs is shown in Table 39 (comparison between allopurinol and 
placebo at start and end of study), Table 40 (comparison between start and end of 
study by treatment group) and illustrated in Figure 55 below. 
 
 
 
Allopurinol 
Visit 2 
(95% CI) 
Placebo 
Visit 2 
(95% CI) 
p 
Allopurinol 
Visit 6 
(95% CI) 
Placebo 
Visit 6 
(95% CI) 
p 
Pre-cuff VTI 
(m) 
0.18 
(0.13 to 0.22) 
0.17 
(0.13 to 0.20) 
0.78 
0.15 
(0.11 to 0.19) 
0.15 
(0.11 to 0.19) 
0.99 
Post-cuff VTI 
(m) 
0.54 
(0.38 to 0.70) 
0.51 
(0.40 to 0.62) 
0.96 
0.41 
(0.33 to 0.50) 
0.44 
(0.33 to 0.55) 
0.71 
Table 39 – Comparison of brachial artery VTI (allopurinol vs placebo) 
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Allopurinol 
Visit 2 
(95% CI) 
Allopurinol 
Visit 6 
(95% CI) 
p 
Placebo 
Visit 2 
(95% CI) 
Placebo 
Visit 6 
(95% CI) 
p 
Pre-cuff VTI 
(m) 
0.18 
(0.13 to 0.22) 
0.15 
(0.11 to 0.19) 
0.34 
0.17 
(0.13 to 0.20) 
0.15 
(0.11 to 0.19) 
0.80 
Post-cuff VTI 
(m) 
0.54 
(0.38 to 0.70) 
0.41 
(0.33 to 0.50) 
0.27 
0.51 
(0.40 to 0.62) 
0.44 
(0.33 to 0.55) 
0.58 
Table 40 – Comparison of brachial artery VTI (start vs end of study) 
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Figure 55 – Comparison of brachial artery VTI 
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3.9 ABI 
As noted in Table 7, the baseline ABI on the affected leg was similar for both groups.  
Table 41 outlines the 95% confidence intervals for the values and compares allopurinol 
with placebo at both start and end of study.  Table 42 compares the values at the start 
and end, splitting by treatment group.  The data is represented graphically in Figure 56. 
 
 
Allopurinol 
Visit 1 
(95% CI) 
Placebo 
Visit 1 
(95% CI) 
p 
Allopurinol 
Visit 6 
(95% CI) 
Placebo 
Visit 6 
(95% CI) 
p 
ABI 
(ratio) 
0.61 
(0.56 to 0.66) 
0.60 
(0.55 to 0.65) 
0.65 
0.63 
(0.58 to 0.68) 
0.63 
(0.57 to 0.69) 
0.93 
Table 41 – ABI measures (allopurinol vs placebo) 
 
 
 
Allopurinol 
Visit 1 
(95% CI) 
Allopurinol 
Visit 6 
(95% CI) 
p 
Placebo 
Visit 1 
(95% CI) 
Placebo 
Visit 6 
(95% CI) 
p 
ABI 
(ratio) 
0.61 
(0.56 to 0.66) 
0.63 
(0.58 to 0.68) 
0.67 
0.60 
(0.55 to 0.65) 
0.63 
(0.57 to 0.69) 
0.39 
Table 42 – ABI measures (start vs end of study) 
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Figure 56 – ABI measures 
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3.10 Walking Impairment Questionnaire 
As outlined in section 2.8.4, a Walking Impairment Questionnaire was administered at 
Visit 2 (second screening visit), Visit 4 (mid-point) and Visit 6 (final study visit). 
 
As well an overall score the WIQ results may be broken down into the three domains 
of distance, speed and climb, as showing in the following sections.  Lower scores 
correspond to poor walking distance/speed and increased pain. 
 
  
156 
 
3.10.1 Overall WIQ scores 
WIQ scores were initially compared at each stage to check for significant differences 
between treatment and placebo groups. 
Time point 
Allopurinol 
(95% CI) 
Placebo 
(95% CI) 
P 
(between group 
comparison at each 
time point) 
Baseline 
(score) 
132.9 
(108.7 to 157.1) 
140.0 
(111.1 to 168.8) 
0.92 
Visit 4 
(score) 
163.0 
(131.5 to 194.6) 
166.3 
(137.4 to 195.3) 
0.09 
Visit 6 
(score) 
139.7 
(96.2 to 183.2) 
146.1 
(111.8 to 180.3) 
0.34 
Table 43 – Overall WIQ scores at different study stages 
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Figure 57 – Overall WIQ scores at different study stages 
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The difference in scores between start, middle and end of the study for both groups 
was then considered, as shown in Table 44. 
 
Time point 
Baseline 
(95% CI) 
Visit 4 
(95% CI) 
Visit 6 
(95% CI) 
P 
(within group 
comparison at 
across the study 
period) 
Allopurinol 
(score) 
132.9 
(108.7 to 157.1) 
163.0 
(131.5 to 194.6) 
139.7 
(96.2 to 183.2) 
0.92 
Placebo 
(score) 
140.0 
(111.1 to 168.8) 
166.3 
(137.4 to 195.3) 
146.1 
(111.8 to 180.3) 
0.13 
Table 44 – Comparison between overall WIQ scores across study stages 
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3.10.2 WIQ distance scores 
 
Time point 
Allopurinol 
(95% CI) 
Placebo 
(95% CI) 
p 
Baseline 
(score) 
41.6 
(29.4 to 53.8) 
46.0 
(33.7 to 58.3) 
0.26 
Visit 4 
(score) 
52.8 
(38.8 to 66.8) 
54.9 
(43.7 to 66.0) 
0.40 
Visit 6 
(score) 
39.6 
(22.3 to 57.0) 
47.0 
(33.4 to 60.7) 
0.32 
Table 45 – WIQ distance scores at different study stages 
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Figure 58 – WIQ distance scores at different study stages 
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3.10.3 WIQ speed scores 
 
Time point 
Allopurinol 
(95% CI) 
Placebo 
(95% CI) 
p 
Baseline 
(score) 
37.1 
(29.4 to 44.8) 
39.8 
(30.0 to 49.5) 
0.75 
Visit 4 
(score) 
43.8 
(31.0 to 56.6) 
51.1 
(39.8 to 62.4) 
0.26 
Visit 6 
(score) 
41.2 
(26.2 to 55.1) 
41.8 
(30.1 to 53.4) 
0.78 
Table 46 – WIQ speed scores at different study stages 
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Figure 59 – WIQ distance scores at different study stages 
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3.10.4 WIQ climb scores 
 
Time point 
Allopurinol 
(95% CI) 
Placebo 
(95% CI) 
p 
Baseline 
(score) 
54.2 
(43.0 to 65.3) 
54.2 
(41.6 to 66.7) 
0.98 
Visit 4 
(score) 
66.4 
(54.4 to 78.4) 
60.4 
(50.0 to 70.9) 
0.69 
Visit 6 
(score) 
58.9 
(43.4 to 74.4) 
57.2 
(44.5 to 70.0) 
0.89 
Table 47 – WIQ climb scores at different study stages 
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Figure 60 – WIQ distance scores at different study stages 
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3.11 SF-36 Quality of Life Questionnaire 
As outlined in section 2.8.5, an SF-36 questionnaire to assess quality of life was 
administered at Visit 2 (second screening visit), Visit 4 (mid-point) and Visit 6 (final 
study visit). 
 
The SF-36 questionnaire consists of scores in a number of domains: 
 Physical functioning score 
 Role functioning physical score 
 Role functioning emotional score 
 Energy fatigue score 
 Emotional well-being score 
 Social functioning score 
 Pain score 
 General health score 
 Health change score 
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3.11.1 Overall SF-36 scores 
SF-36 scores were initially compared at each stage to check for significant differences 
between treatment and placebo groups. 
Time point 
Allopurinol 
(95% CI) 
Placebo 
(95% CI) 
p 
Baseline 
(score) 
535.1 
(457.7 to 612.5) 
571.0 
(519.5 to 622.4) 
0.73 
Visit 4 
(score) 
525.0 
(439.0 to 610.9) 
552.1 
(472.9 to 631.3) 
0.62 
Visit 6 
(score) 
555.2 
(485.0 to 625.5) 
536.5 
(470.8 to 602.2) 
0.57 
Table 48 – Overall SF-36 scores at different study stages 
No significant change across visits was noted (p=0.92 for allopurinol; p=0.70 for 
placebo) 
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Figure 61 – Overall SF-36 scores at different study stages 
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3.11.2 SF-36 domains 
The various domains of the SF-36 questionnaire were then considered separately. 
 
Domain Time point 
Allopurinol 
(SD) 
Placebo 
(SD) 
P 
Physical 
functioning 
score 
Baseline 49.7 (20.7) 52.8 (17.3) 0.98 
Visit 4 48.2 (21.5) 49.8 (18.3) 0.89 
Visit 6 53.4 (21.4) 45.7 (18.8) 0.12 
Role 
functioning 
physical score 
Baseline 60.0 (43.3) 56.0 (39.7) 0.70 
Visit 4 52.2 (46.4) 53.4 (46.4) 0.81 
Visit 6 48.9 (43.0) 47.0 (40.9) 0.91 
Role 
functioning 
emotional 
score 
Baseline 74.7 (38.8) 84.0 (34.9) 0.26 
Visit 4 75.4 (40.4) 69.7 (41.0) 0.56 
Visit 6 80.4 (33.6) 78.8 (35.0) 0.89 
Energy fatigue 
score 
Baseline 55.0 (23.0) 59.5 (18.6) 0.67 
Visit 4 52.4 (26.4) 57.3 (19.4) 0.62 
Visit 6 60.7 (19.0) 53.2 (22.8) 0.34 
Emotional well 
being score 
Baseline 71.2 (26.3) 79.2 (19.1) 0.21 
Visit 4 70.6 (30.9) 79.8 (18.8) 0.35 
Visit 6 80.7 (13.1) 76.0 (24.4) 0.95 
Social 
functioning 
score 
Baseline 71.3 (30.0) 86.7 (17.8) 0.06 
Visit 4 71.8 (31.3) 82.2 (21.6) 0.40 
Visit 6 76.5 (24.4) 80.9 (24.3) 0.47 
 
(continued on next page) 
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Domain Time point 
Allopurinol 
(SD) 
Placebo 
(SD) 
P 
Pain score 
Baseline 59.0 (26.6) 56.8 (21.8) 0.63 
Visit 4 56.3 (31.8) 56.6 (24.5) 0.98 
Visit 6 53.7 (28.7) 56.1 (21.1) 0.80 
General health 
score 
Baseline 49.2 (26.1) 51.0 (21.8) 0.96 
Visit 4 51.3 (27.0) 54.5 (23.8) 0.68 
Visit 6 57.4 (19.2) 54.5 (24.7) 0.85 
Health change 
score 
Baseline 45.0 (17.7) 45.0 (17.7) 1.00 
Visit 4 46.7 (11.4) 48.9 (18.1) 0.48 
Visit 6 43.5 (15.5) 44.3 (13.2) 0.99 
Table 49 – SF-36 scores by visit and domain 
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3.12 Oxidised LDL 
Oxidised LDL levels were measured both at baseline (Visit 1), midpoint (Visit 3) and end 
of study (Visit 6).  The results were as noted in Table 50 and Figure 62. 
 
Time point 
Allopurinol 
(95% CI) 
Placebo 
(95% CI) 
p 
Baseline 
(U/l) 
53.0 
(45.7 to 60.3) 
49.4 
(43.1 to 55.8) 
0.62 
Visit 3 
(U/l) 
45.2 
(39.1 to 51.3) 
49.4 
(41.9 to 57.0) 
0.46 
Visit 6 
(U/l) 
57.2 
(44.8 to 69.6) 
45.8 
(39.2 to 52.4) 
0.21 
Table 50 – Oxidised LDL results by visit 
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Figure 62 – Oxidised LDL results by visit 
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Difference in scores between start, middle and end of the study for both groups was 
then considered, as shown in Table 51. 
 
 
Time point 
Baseline 
(95% CI) 
Visit 3 
(95% CI) 
Visit 6 
(95% CI) 
p 
Allopurinol 
(U/l) 
53.0 
(45.7 to 60.3) 
45.2 
(39.1 to 51.3) 
57.2 
(44.8 to 69.6) 
0.15 
Placebo 
(U/l) 
49.4 
(43.1 to 55.8) 
49.4 
(41.9 to 57.0) 
45.8 
(39.2 to 52.4) 
0.66 
Table 51 – Oxidised LDL results by treatment group 
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4 Discussion 
This double-blind, placebo controlled, parallel group study aimed to evaluate whether 
treatment with allopurinol for six months would prolong exercise duration in patients 
with PAD.  In this section the findings of the study (already presented in the results 
section) will be discussed and the possible underlying mechanisms for these findings, 
along with the strengths and limitations of this study, will be considered. 
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4.1 Primary outcome – treadmill testing 
The results of the treadmill testing are laid out in Section 3.5.  As explained in the 
methods, there are two key items that are conventionally measured when carrying out 
a treadmill test – claudication onset distance and peak walking distance.  In both of 
these there was a slight trend to higher baseline values in the placebo group (despite 
the significantly higher pack year history in this group), however these did not reach 
statistical significance.  By the end of the study both measures had increased in each 
arm of the study – this was of the order of 40m for COD and 27m for PWD, again with 
no significant difference between active and placebo groups, although if anything the 
increase in the placebo groups was higher.  This increase over time in walking distance 
in the placebo arm is something that has been recognised previously in studies of PAD 
and will be discussed further below.223 
 
To see if there was any sub-group that was showing benefit from allopurinol the 
treadmill results were then split into those with high/low baseline COD/PWD and 
those with high/low baseline uric acid/systolic BP and ABI.  None of these subdivisions 
made any change to the results and there remained no statistically significant 
difference between the two groups following six months of treatment.  It should 
however be emphasised that the study was not powered to evaluate sub-groups, as 
this meant comparisons were between very small numbers (12-13 participants per 
group).  These sub-group analyses have been included to help demonstrate that the 
data has been fully explored and that, as such, any small potential benefit had not 
been overlooked – had there been any positive results from the sub-groups these 
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would only have been able to have been taken as an indication of potential than a firm 
result. 
 
The reasons for why allopurinol should potentially be of benefit in PAD were discussed 
in the introduction – in particular Section 1.4 outlined the other disease processes in 
which it has been shown to be useful.  In this study, despite a clear reduction in uric 
acid in the group treated with allopurinol, there has been no evidence of any beneficial 
effect on walking distance when on the treadmill.  This may be due to problems with 
treadmill testing as an outcome measure (i.e. there is an effect but it is not detecting 
it), or it may be that PAD is a different disease process that is not amenable to 
improvement with allopurinol.  Each of these possible explanations will now be 
considered in turn. 
 
4.1.1 Treadmill testing as an outcome measure 
It has been previously recognised that there are difficulties with monitoring treadmill 
performance over time due to increases in maximal walking distance following 
repeated testing.  This is particularly the case with constant-load treadmill protocols, 
where both speed and grade remain constant throughout the test – the co-efficient of 
variation on this type of test can be almost 45%.  Switching to a graded approach 
(where speed is constant but the grade gradually increases) can reduce the co-efficient 
of variation to 15-25%, although it does still remain an issue.20 
 
This improvement in exercise distance over time in patients not on active therapy 
limits the ability to assess treatment effect in study subjects.  The mechanism 
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underlying this effect is unknown but may represent a “learning curve” as patients 
repeat the test, a classic placebo effect, or it may be due to improved walking 
biomechanics as subjects become familiar with the treadmill apparatus.20  It has also 
been previously reported that the placebo effect is particularly strong in conditions 
where pain is a major factor, as is the case with PAD, therefore an endpoint that 
relates to pain is more likely to be influenced by placebo effect.223 
 
Evidence to date suggests that although both COD and PWD should be recorded it is 
the latter that has been found to be more reproducible.  This is perhaps counter to the 
patient’s perspective – they are probably more concerned about an increase in COD 
following treatment as this will have greater impact on the range of activities that they 
can undertake with minimal symptoms.  Most patients will continue to walk after 
appearance of the first signs of pain (COD), but few will walk until their maximum pain 
threshold (PWD) is reached during the course of daily activities.224  In practical terms 
however many study participants had difficulty with knowing when to indicate they 
had developed pain – some felt an occasional early twinge that settled briefly before 
returning later, many forgot to mention it at all without repeated prompting as it was 
just something they were so accustomed to in day-to-day life. 
 
An interesting study conducted by Gardner et al in 1991 looked at the effect that 
handrail support had on patients with PAD undergoing treadmill testing.225  They found 
that both COD and PWD were significantly greater when patients were allowed to use 
the handrails for support.  The magnitude of increase was around 10m in COD and 
almost 75m in PWD.  They also found that these distances tended to increase upon 
171 
 
repeated testing when handrail support was allowed.  There were no significant 
changes in foot transcutaneous oxygen tension and ABIs following exercise to 
maximum tolerable pain, regardless of handrail support.  They concluded that due to 
the alterations in claudication distances handrail support should not be allowed when 
assessing patients with PAD, unless balance cannot otherwise be maintained.  In this 
study there was no strict policy regarding use of the handrails.  Some patients hardly 
used them, others did utilise them.  If asked they were advised to use them as required 
but their usage was not recorded.  In retrospect it may have aided consistency to have 
tried to minimise handrail use except for those patients who really required it.  Nicolaï 
et al also confirmed that walking distances were greater when a steady 
speed/progressive incline protocol was used, as opposed to a single-stage protocol.  
This is something that has been previously recognised and was the reason for the 
Gardner protocol being used in this study.224 
 
Treadmill testing was however not the only method of assessment used in this project.  
Zwierska et al showed in 2004 that shuttle walk testing exhibits similar test-retest 
reliability as treadmill testing, but that it evoked a lower level of cardiovascular stress 
and is preferred to treadmill testing by a large proportion of patients.226  Based on 
previous usage in patients with PAD it was decided that a variation on this (the 6MWT) 
would be used in this study.207  Qualitative feedback from patients comparing the 
6MWT and the treadmill test indicated that the majority preferred the 6MWT and 
found it to be more akin to their normal day-to-day routine (especially being allowed 
to stop if required), however some preferred the physical support of the treadmill 
machine and the handrails.  Given the variable walking ability of the patients in the 
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study and the aforementioned problems with treadmill testing (despite its wide usage 
in PAD studies) it was useful to have made use of both methods of assessment. 
 
4.1.2 PAD as a different disease process 
We know that allopurinol has been shown to be of benefit in angina, in some ways a 
similar disease process, yet in this study it has not been of benefit in patients with PAD.  
Rekhraj et al showed that allopurinol reduced LV end systolic volume and LV afterload 
(as measured by augmentation index) in patients with ischaemic heart disease, which 
suggests that offloading the LV may be another mechanism contributing to the anti-
ischaemic effect of allopurinol in angina pectoris.188  This possibility is highly relevant 
to the work in this thesis since this particular effect on LV afterload would produce an 
anti-ischaemic effect on the heart but not an anti-ischaemic effect in PAD. 
 
As discussed earlier, oxidative stress is part of the disease process of PAD.  Edwards et 
al found that exercise in patients with PAD leads to a neutrophilia and thromboxane 
production with subsequent endothelial injury.  The antioxidant activity of glutathione 
peroxidase was also reduced in patients with claudication and this may allow the 
unopposed action of free radicals to damage endothelium.227  One would therefore 
hope that helping to address this oxidative stress with allopurinol would be of benefit.  
Indeed Mellin et al. showed a reduction of ROS, using electron spin resonance 
spectroscopy, acutely after initiation of allopurinol.  However long-term treatment did 
not sustain this reduction.156  This lack of long-term benefit may be due to the 
breakthrough of other sources of ROS production such as NADPH oxidase and may be 
a potential reason for the lack of symptomatic benefit.130, 159, 161  Gresele et al made a 
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similar attempt to offset the effects of ROS, this time by increasing the levels of 
circulating NO via an NO-donating agent (NCX 4016) – they found no improvement in 
PWD.228 
 
A small (12 patient) study of young asymptomatic individuals with familial 
hypercholesterolemia found endothelial XO activity to be increased by >200% 
compared with age-matched controls, suggesting that activation of vascular XO may 
represent an early mechanism contributing to increased radical formation and 
endothelial dysfunction in the atherosclerotic disease process.127  This may indicate 
that XO blockade may have a role earlier in the disease process, however by the time 
the disease has become established (such as in the PAD patients in this study) it is less 
likely to have a beneficial effect. 
 
With PAD we are also dealing with a different calibre of vessel.  The coronary arteries 
at their largest (the left main stem) measure 4.5±0.5mm, falling to 1.9±0.4mm in the 
distal left anterior descending artery.229  By comparison the peripheral arteries in the 
legs are more than twice this diameter – with the common femoral artery having a 
diameter of 9.3±1.1mm, falling to 4.9±0.6mm when it reaches the distal popliteal 
artery.230  Therefore when looking at the absolute level of increase in vessel 
compliance that may be possible through improving oxidative stress (as shown in the 
positive effects of allopurinol on FMD in many other studies) it can be seen that this is 
likely to produce less of a relative increase in vessel diameter (and thus potential blood 
flow) in these larger arteries.  This may also be why endovascular approaches to 
treatment of PAD have been less successful than similar approaches in the smaller 
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calibre coronary arteries, where stenting has been highly efficacious.  It is well 
recognised in coronary angioplasty that an underexpanded stent is more likely to 
restenose – with the size of peripheral vessels being considered in PAD it may be 
difficult to ensure adequate expansion, where in general there has been less use of 
intravascular ultrasound techniques.  There are newer imaging techniques, such as 
optical coherence tomography, which offer enhanced imaging resolution and contrast 
that may prove of help in this area.231  The additional information provided via these 
imaging modalities has provided useful further information about the progression of 
atherosclerosis.  In particular it appears that the decrease in luminal area cannot be 
attributed to solely the increase in plaque – arterial wall shrinkage (mainly through loss 
of the internal elastic lamina) is a paradoxical mechanism that may contribute to the 
severe luminal narrowing of the atherosclerotic femoral artery.232  Imaging has also 
helped with the development of new balloon technologies, such as ‘cutting balloons’ 
that have proved helpful in improving outcomes in cases of restenosis.233 
 
When one considers other drugs that are of benefit in cardiac disease it can be seen 
that many of them (with the exception of anti-platelet agents) have not been shown to 
have been of benefit in PAD.  For example vasodilators were initially hoped to be a 
useful treatment for claudication symptoms, yet repeated studies have found no 
benefit for clinical efficacy.  In an excellent review article on the topic of 
pharmacotherapy in PAD, Hiatt explains the likely pathophysiology for this.  It is 
thought likely to be because during exercise, the portion of a resistance vessel located 
distally to a stenosis or occlusion dilates in response to ischaemia.  Vasodilators do not 
affect these vessels, whose dilation is due to endogenous factors, but they may 
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decrease resistance in other vessels, leading to a “steal” of blood flow away from the 
under-perfused muscle. Vasodilators can also lower systemic pressure, leading to a 
reduction in perfusion pressure.48 
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4.2 Secondary outcomes 
4.2.1 Six Minute Walk Test 
Baseline distances walked during the 6MWT were very similar for both groups (mean 
401.2m allopurinol vs 389.1m placebo, p=0.72).  There was no meaningful change in 
these levels throughout the study period.  Given the variable baseline walks for each 
participant the mean absolute and relative change at mid-point and end of study was 
also calculated.  This showed a very small trend towards a ‘learning effect’ (as 
discussed further under strengths and limitations in section 4.3), but in practical terms 
there was no real change, certainly not of the 30m or so level that would be 
considered clinically meaningful (and that the study was therefore powered to detect). 
 
The 6MWT results were then sub-divided in two further ways – by baseline walk and 
uric acid.  The first split participants along the median baseline walk to see if any effect 
was restricted to good or poor walkers – this made no significant change to the results.  
For uric acid both median baseline uric acid level and those with high/low percentage 
reduction in uric acid were considered – again this did not change the results and there 
remained no clinically meaningful change in distance walked. 
 
The underlying reasons for this lack of response on 6MWT are likely similar to those 
discussed in the previous section for treadmill testing.  Given the different nature of 
the stress provided by this test compared to treadmill testing it was still something 
that was worth assessing – indeed many study participants remarked that they felt this 
test was a better reflection of their ‘real world’ walking pattern, particularly with the 
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ability to stop and take a break if required.  There is some evidence that 6MWT 
performance is more closely correlated with physical activity during daily life than 
treadmill measures.234  It also remains a useful test in a prognostic sense across a wide 
variety of disease processes and is one that is easily tolerated by patients with a 
number of exercise-limiting conditions.235-239 
 
As mentioned in the previous section an alternative to the 6MWT is the shuttle walk 
test (SWT).  In this test an audio tone sounds at a pre-defined interval – the participant 
has to reach the cone by the time the tone sounds.  This has a similar advantage to the 
6MWT in that it provides a challenge closer to the patient’s usual way of walking than 
that observed with the treadmill, but has the advantage of having the patient’s speed 
controlled externally, allowing for a progressive increase of the walking effort and thus 
perhaps better potential for revealing the patient’s functional capacity.  However, 
traditionally the SWT has not been widely utilised with PAD patients, and its 
psychometric characteristics (given the need to reach a target on every lap and the 
sense of failing against a standard rather than just being asked to do as much as they 
can manage) still need to be evaluated with this population and contrasted with 
different protocols concerning functional assessment.219 
 
4.2.2 Blood pressure 
As mentioned in Section 3.7, BP had not been identified as a key secondary outcome 
measure for the study.  Therefore although baseline values were collected as part of 
the initial physical examination the subsequent readings were taken prior to 6MWT 
exercise and thus (due to the organisation of the visits) this was mainly following 
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administration of GTN spray for FMD.  Given the effect this has on BP it was therefore 
only possible to compare post-GTN readings between Visit 2 and Visit 6.  There was no 
significant change noted between these visits – however the level of reduction 
normally noted by treatment with allopurinol is likely to have been masked by the 
magnitude of drop in BP following GTN administration.  Comparing the mean BP in the 
baseline characteristics (i.e. without GTN) with the post-FMD result shows a reduction 
from 155/78mmHg to 120/69mmHg. By comparison with allopurinol the magnitude of 
reduction that would be expected would be of the order of 3/1mmHg.170  This small 
change will easily be obscured by the much more marked effect of GTN administration 
and thus it is not possible to properly comment in this study on any effect on 
participants’ blood pressure from treatment with allopurinol.  Nevertheless the vast 
majority of studies of allopurinol found no significant effect of allopurinol on BP. 
 
4.2.3 FMD 
The results of FMD testing are shown in Section 3.8.  It can be seen that the baseline 
values were similar in both active and placebo groups.  The relative change in vessel 
diameter following hyperaemia (i.e. post BP cuff deflation) was very slightly better in 
the allopurinol group, however the absolute level was still very small (<0.5%) and the 
difference between active and placebo groups was not statistically significant. 
 
Following administration of GTN there was a single result that was statistically 
significant (visit 5), however this was only for the relative change within that visit – 
when compared to baseline it was no longer significant. 
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There was no significant change in brachial artery blood flow (as measured by VTI) in 
either group following treatment. 
 
Although these findings are in-keeping with other outcome measures in this trial, a 
number of other studies of allopurinol have previously shown an improvement in FMD.  
For example, Rekhraj et al showed an improvement following allopurinol treatment of 
+0.82±1.8% vs. placebo -0.69±2.8%; p=0.017.188  This was after nine rather than six 
months of treatment, however even looking at six months in their study, there was a 
clear separation between the two groups.  The magnitude of the change was not that 
much greater than that seen here, however the spread of results was much tighter. 
 
One other recent study of allopurinol found no effect on endothelial function.  
Szwejkowski et al postulated that the lack of effect on FMD results in their study may 
be that their patients with type II diabetes mellitus were very well treated with statins, 
A E inhibitors and A B’s which are each known to improve endothelial function.  They 
went on to explain that this was evident in the baseline measures of vascular health in 
their patients – the baseline augmentation index was only 11% therefore potentially 
making it difficult to improve it further with allopurinol.190  Augmentation index was 
not a measure that we elected to use in this study. 
 
FMD is a useful non-invasive test in patients at risk of cardiovascular disease.  Muiesan 
et al showed that in hypertensive patients FMD (but not endothelium-independent 
dilatation by way of GTN) helped identify those at risk of non-fatal and fatal 
cardiovascular events.240  However as clearly outlined by Corretti et al, it is a test that 
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can be influenced by many factors and the results can be confounded by these 
factors.173  For example in ideal conditions they explain that all vasoactive medications 
should be withheld for at least four half-lives.  It could however be argued that as we 
were looking at allopurinol as an add-on therapy it would not have been appropriate 
to have done this as it would not have represented a fair comparison against current 
medical treatment.  It is also advised that subjects should fast at least eight to 12 hours 
before the study, should not exercise, or ingest substances that might affect FMD such 
as caffeine, high-fat foods and vitamin C or use tobacco for at least four to six hours 
before the study.  In practical terms with my study population it was not always 
possible to reliably take account of these factors.  In particular some patients could not 
easily attend morning appointments and those who continued to smoke were not 
keen to abstain from doing so prior to study visits, or did so intermittently.  These 
factors may have combined to lessen the effect of any change in FMD readings.  There 
is certainly good evidence from invasive testing of the role that cigarette smoking has 
on impairing vascular function.241 
 
It also has to be considered that the patient population being studied here, all with 
proven PAD, had stiffer vessels that were less likely to respond to treatment.242-244  
Interestingly in patients with end-stage renal disease (another group with more 
calcified and less-compliant arteries) there was also less evidence of utility of FMD 
measurement by way of prognostic value.245  A study by Payvandi et al showed that in 
PAD patients undertaking exercise, those with higher   levels of physical activity had a 
greater percentage change in brachial artery FMD.243  This was an observational study 
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but it could mean that those able to maintain higher levels of activity are patients with 
milder disease. 
 
4.2.4 ABI 
No significant change in ABI was noted between the start and end of the study in the 
two groups – the mean ratio remained approximately 0.61.  This is consistent with the 
lack of clinical response to treatment. 
 
When considering alternative treatments for PAD, a small number of studies using 
cilostazol have compared ABI pre and post treatment.  The weighted mean difference 
for the mean change in ABI was in favour of treatment with cilostazol to a small degree 
(WMD 0.06; 95% CI: 0.03 to 0.09) compared with placebo.67  A Cochrane review of 
numerous studies of pentoxifylline found none that reported any significant change in 
ABI following treatment – at most there was a very small non-significant trend to 
improvement, but in many no change was reported.72 
 
There are some issues with the standardisation of measurement of ABIs between 
centres, although this was not something that impacted on this study given all 
measurements were carried out by AR.246  It could however be argued that repeated 
measurements would have been valuable in ensuring maximum accuracy.247  ABI 
remains a valuable tool in both initial assessment of patients with PAD and in a 
prognostic sense with regards future cardiovascular events.245, 248 
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4.2.5 Questionnaires 
There were no significant changes in either the general quality of life questionnaire 
(SF-36) or the disease-specific Walking Impairment Questionnaire.  This is in-keeping 
with the lack of difference in either COD or PWD between treatment and placebo 
groups. 
 
The WIQ has been well-validated in the PAD population, in particular there is good 
correlation between claudication onset/peak walking distances and WIQ pain, speed, 
and distance subscales. Overall the WIQ is said to be the most specific questionnaire 
for documenting the qualitative deficits of the patient with claudication while 
providing strong relationships with the quantitative measures of arterial disease.249  It 
was therefore an appropriate choice of questionnaire in this study and the lack of 
improvement in scores for those participants receiving allopurinol is unsurprising given 
the lack of change in the primary outcome.  Indeed if there had been a positive result 
in this area it would have been surprising given the known correlation with objective 
measures. 
 
SF-36 is a much more general (albeit widely utilised) questionnaire and again the lack 
of improvement in scores here is not surprising given the lack in change in objective 
measures.  In most domains there was a trend to slightly higher scores in the placebo 
group at baseline, however none of the differences reached statistical significance and 
this is likely just a consequence of the slightly small sample size involved.  There were 
no significant changes following treatment. 
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4.2.6 Oxidised LDL 
Evaluation of oxidative stress is a difficult task in vivo due to the very short half-life of 
ROS.  However the consequence of ROS activity, by way of lipid peroxidation, is 
something that can be measured.250-252  In this study oxidised low-density lipoprotein 
was chosen.  No significant changes were found in Oxidised LDL levels in either 
treatment or placebo groups throughout the duration of the study. 
 
However of interest is the level of Ox-LDL detected in this patient population.  The 
mean baseline levels were in the 43-60 U/l range (51.2±16.6U/l), which seems to be 
quite low in comparison to some other studies.  For example a population study of 35-
55 year olds by Langlois et al looked at femoral and carotid wall damage via ultrasound 
imaging.  When these measurements were compared with Ox-LDL levels they found 
that males had generally higher levels than females and that those with evidence of 
femoral and carotid artery damage had higher levels than those without.  The Ox-LDL 
levels for those without evidence of wall damage were 87.9±37.2U/l (female) and 
93.3±36.1U/l (male), rising to 107.3±49.3U/l (female) and 110.7±41.3U/l (male) in 
those with damage to both vessels.253 
 
By comparison a study of 72 young (30±10 years) healthy Spanish subjects found levels 
of 58.4±13.6U/l (female) and 68.1±17.7U/l (male).254  These levels appear to be more 
in line with the levels found in this study – this is surprising as one would have 
expected to have found higher levels here given the degree of arterial damage evident.  
However another comparator is the baseline levels in patients with type II diabetes 
and left ventricular hypertrophy in the study by Szwejkowski et al – these were in the 
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range of 28.5±9.9U/l and did not significantly change following treatment with 
allopurinol.190  Kao et al had similar baseline values of 31.1±8.85U/l in their study of 
patients with chronic kidney disease and found a trend towards slight improvement in 
the active group, although it did not reach statistical significance.189  A study of 107 
healthy adults stratified by uric acid levels showed a trend towards increased Ox-LDL 
levels with increasing serum uric acid levels (from 55.7±16.0U/l [1st quartile, UA 
<5.3mg/dl] to 60.3±18.2U/l [4th quartile, UA>7.0mg/dl]) but these differences were not 
found to be statistically significant.179 
 
This marked variability in levels between different studies may be related to the levels 
of disease activity but could also be due to the technical differences in measuring Ox-
LDL levels between different laboratories and different assays, as discussed further 
below.  The comparators from Szwejkowski and Kao were both analysed using the 
same process/equipment as in this study. 
 
Much of the published work in PAD appear to look more at anti-Ox-LDL antibody levels 
that than Ox-LDL levels themselves, however one study from Andican et al in 2008 did 
measure Ox-LDL.  They considered 42 patients, half with angiographically-proven PAD 
and half as ‘healthy controls’.  The Ox-LDL levels in the control group were 
72.2±20.1U/l and in the PAD group were 87.0±24.7U/l.255  The higher levels in their 
PAD group were statistically significant, however it should also be noted that there was 
an almost 15 year mean age difference between their control and PAD groups 
(p<0.001) and their PAD group were almost exclusively male compared to a 50/50 split 
in the control group (p<0.01) – this makes it more difficult to solely attribute the 
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difference to be due to PAD given the existing evidence that increasing age, cholesterol 
and male sex lead to higher Ox-LDL levels.  Interestingly when they split their PAD 
group into those with mild vs severe disease by Fontaine grading there was almost no 
difference – 88.3±21.5U/l (mild) vs 85.5±28.8U/l (severe). 
 
In terms of this study however, these low levels of Ox-LDL at baseline would certainly 
go some way to explaining the lack of response to allopurinol.  Why they are so low is 
however unclear given the clear disease burden in the patient population.  One could 
also postulate that given the majority of patients in this study were ex-smokers rather 
than active smokers their Ox-LDL levels may be slightly lower.  There is also some 
evidence that measuring the anti-Ox-LDL antibody levels may give more stable results 
than the more complex process of directly measuring Ox-LDL levels.256  However there 
are many different auto-antibody assays available, which can give quite varying 
outcomes themselves, therefore picking the correct one would be important.257 
 
Although comparing different Ox-LDL values between different published studies is 
informative to some extent, such results should not be over-interpreted, especially 
between different laboratories. 
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4.3 Strengths & limitations 
As a double-blind placebo-controlled parallel group study both the participants and 
investigators were blind to treatment.  All data collection was carried out by a single 
investigator, eliminating inter-observer variability.  The ongoing participation rate was 
good, with few patients leaving prior to completion.  There was an equal balance 
between both arms of study with respect to withdrawals, with three in the active arm 
and two in the placebo group (see CONSORT diagram, Figure 20).  The numbers that 
did leave were lower than predicted and the study appears to have been appropriately 
powered, with no evidence of any trend towards a positive result that was just below 
the level of statistical significance – it was clearly negative. 
 
As well as higher than expected numbers remaining in the study, the level of uric acid 
reduction was also very good – as outlined in section 3.3 the majority of participants in 
the active arm experienced a 40-60% drop in uric acid levels.  This is higher than the 
levels achieved in a number of other trials and is no doubt due to the high dose 
(600mg/day) of allopurinol being used.164  This dose was well-tolerated with 
withdrawals from the study occurring prior to the final dose increase.  At the start of 
the study there was noted to be a degree of confusion amongst some participants 
regarding the different IMP doses/bottles.  A guidance sheet (Appendix F) was 
therefore created and this proved to be very effective in resolving the matter. 
 
There was good use (over 90%) of anti-platelet and statin therapy in all patients prior 
to entry into the study, as per guidelines for management of PAD.  There were very 
few changes to medication amongst participants during study participation.  Baseline 
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characteristics between the groups were broadly similar, with the exception of pack 
years smoked – this was higher in the placebo group (49.7 years v 31.7 years in the 
active group).  Although this difference did reach statistical significance (p=0.04) there 
remained a long smoking history in the placebo groups and baseline ABIs were almost 
identical. 
 
The choice of primary and secondary endpoints was consistent with other major trials 
of PAD, with absolute walking distance evaluated by treadmill testing being the most 
widely utilised approach.67  The degree of clinical improvement that was being sought 
was also in line with other trials of PAD treatment.25, 67  However, as discussed above 
there are problems with treadmill testing – in particular it may have been beneficial to 
have had clear guidance regarding the use of handrails. 
 
The study was however a single-centre concern, with relatively small numbers of 
participants in absolute terms.  This did mean though that there was a consistency of 
approach in assessment of patients and a close adherence to the study protocols.  
Some issues only become evident after starting the study visits – for example the 
distance of the test rooms from the main entrance to the hospital meant that some 
patients were arriving with pre-existing calf muscle fatigue.  Wheelchair collection 
from the main entrance by AJR was offered to all patients but the majority declined 
this.  In cases where they had accepted it on the first visit they were encouraged to 
persist with this on subsequent visits to ensure consistency.  After the first couple of 
patient visits the administration of questionnaires was moved to the beginning of the 
visit to ensure an adequate rest period prior to undertaking exercise. 
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As noted previously it would have been useful to have consistently recorded 
participants’ BP at start/mid/end of study separate to the administration of GTN to 
allow for assessment of the response of this variable to allopurinol. 
 
There were issues in consistently assessing the claudication onset distance upon 
treadmill testing given the variation between participants in their reporting of pain – 
some would forget to mention it and only volunteer the information upon prompting.  
There was also a clear heterogeneity in the participants with regards severity of PAD – 
some managed to walk only a minute or two on the treadmill before having to stop 
due to pain, yet others were able to manage a much more considerable distance.  In 
some respects this could be seen as a limitation, however in reality it reflects the 
clinical spectrum of PAD.  Attempts were made in the analysis to sub-divide the 
participants into ‘poor’ and ‘good’ walkers both in regards  OD and PWD (sections 
3.5.2 and 3.5.3 respectively) – it could be argued that this sub-division reduced the 
numbers available for analysis by too great a degree (the study was certainly not 
powered for such comparisons), and that greater participant numbers (or a focus on 
particularly good or poor walkers) could have been beneficial, however there did not 
appear to be any trend that would have reached statistical significance with higher 
numbers. 
 
When considering baseline treadmill measurements most studies consider the mean of 
at least two treadmill tests.  However there are varying approaches as to how stability 
is defined.  In this study a <25% change in PWD between the two tests was the pre-
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defined criterion.  However Mohler et al (amongst others) opted for a different 
approach due to the heterogeneous population of PAD patients. 46  They carried out an 
initial screening ETT and then required patients to undergo at least two further 
exercise tests on different days and meet one of the following two criteria: 
1. PWT of between 1 and 5 minutes in the first qualifying exercise test and 
PWT in the second (consecutive) test within 60 seconds of the preceding 
test (both must be greater than 1 minute), or 
2. a PWT of between 5 and 12 minutes in the first qualifying exercise test and 
a PWT in the second or sequential test within 20% of the first (but less than 
12 minutes). The baseline for future comparison was defined as the mean 
of two qualifying treadmill visits. 
This is an interesting approach – on the one hand it is one extra baseline treadmill 
compared to the protocol used in this study and is slightly stricter on those walking >5 
minutes.  However for the 1-5 min walkers it is actually more generous in the degree 
of variation allowed.  This would have made recruitment slightly easier but it could be 
argued that the strict relative difference approach used here should have if anything 
selected patients with more reproducible symptoms. 
 
With regards the 6MWT there is an element of a ‘learning effect’ at play.  This is 
something that has been recognised previously and is felt to be of the order of around 
4.5% in healthy subjects, possibly higher in those with more disease burden.258  It 
tends to decrease with repeated test administration, plateauing after three tests.259  In 
this study only three tests were carried out (baseline/mid/end).  Only a small learning 
effect of around 3% appeared to be present in this study but an increased number of 
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tests would have helped to reduce the impact of this.  This would however have to be 
balanced by the fatigue experienced by patients – further walking tests would have 
either necessitated extra study visits or a much increased visit length to allow for 
sufficient rest, potentially reducing the acceptability of the study protocol to 
participants. 
 
The statistical analyses carried out when looking at the changes in walking distances 
over time could also have been made more robust.  In particular when taking into 
consideration the differing baselines in active and placebo group and the change in 
both over time it would have been more appropriate to use an analytical technique 
that took these factors into account, such as analysis of variance (ANOVA) or 
generalised linear mixed models (GLMM). 
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4.4 Conclusion 
This study showed that treatment with allopurinol did not prolong exercise duration in 
patients with peripheral arterial disease.  As discussed above there may be some issues 
with the reliability of treadmill testing, but the baseline stability criteria were kept 
quite strict to attempt to minimise this.  Of particular relevance is the fact that it was 
not just ETT performance that did not improve – all other measures of exercise, 
vascular health and indeed the participants’ own assessment of their health by way of 
questionnaires did not change. 
 
In view of the excellent reduction in uric acid levels in the allopurinol group this would 
suggest that it is the treatment itself that does not work in this disease process rather 
than a failure to properly appreciate an effect.  Given the large number of anti-anginal 
therapies that are ineffective in PAD it is perhaps not unsurprising that the outcome of 
this trial was negative.  Nevertheless it was an important question to be answered 
given the small number of effective therapies that are on offer to these patients and in 
view of the multitude of other areas in which allopurinol has shown promise. 
 
Given the findings presented here, one would question as to whether further research 
in this area would be worthwhile.  A study involving a larger number of patients and 
either alternative vascular imaging techniques or stricter criteria around handrail use, 
shuttle walk testing and pre-FMD preparation may help to provide an absolutely 
definitive answer – however with no sign of any improvement despite good 
compliance with therapy it would perhaps not be the best use of research funds.  
Equally the use of alternative XO inhibitors such as febuxostat and oxypurinol would 
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not appear to be worthwhile given the levels of uric acid reduction demonstrated in 
this study.  Allopurinol does of course bring other anti-oxidant effects and it may be 
that those could of some benefit in those patients who are earlier in the 
atherosclerotic disease process.  However if one was looking earlier in the disease 
process this would need to be a longer-term project and thus one that would 
potentially be subject to confounding from changes in other variables over time.  By 
comparison the promising results for allopurinol in patients with angina, due probably 
to it off-loading the LV, would suggest that angina is a more fruitful area for further 
research with this drug. 
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Appendices 
Examples of the trial paperwork are shown in the following pages. 
 
All invitation letters, reply slips, study visit letters and post-trial notifications to 
patients were personalised to each participant and generated from the study database 
using the mail merge facility in Microsoft Word. 
 
The CRF was printed as a double-sided booklet, with instructions/study visit progress 
noted on the facing page from the main visit content. 
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K. Post-trial follow-up letters to participants 
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